: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Lung Cancer

Free Subscription

Articles published in J Thorac Oncol
Retrieve available abstracts of 787 articles:
HTML format

Single Articles

July 2024

GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al
Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676.
PubMed Abstract available

JUN S, Shukla NA, Durm G, Hui AB, et al
Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664.
PubMed Abstract available

LIN YL, Wang GS, Wei JC
Rheumatoid Arthritis and Risk of Lung Cancer.
J Thorac Oncol. 2024;19:e15-e16.
PubMed

YANG JJ, Wen W, Zheng W, Shu XO, et al
"Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia".
J Thorac Oncol. 2024;19:e14-e15.
PubMed

SHEN LT, Chen HL
Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia.
J Thorac Oncol. 2024;19:e13-e14.
PubMed

AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al
Lung Cancer in Ghana.
J Thorac Oncol. 2024;19:966-972.
PubMed

MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al
Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
J Thorac Oncol. 2024;19:984-994.
PubMed Abstract available

June 2024

SPICER JD, Cascone T, Wynes MW, Ahn MJ, et al
Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).
J Thorac Oncol. 2024 Jun 18:S1556-0864(24)00627.
PubMed Abstract available

HSU CK, Lai CC
Association Between Rheumatoid Arthritis and the Risk of Lung Cancer.
J Thorac Oncol. 2024;19:e9.
PubMed

URBANSKA EM, Sorensen JB, Santoni-Rugiu E
Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task.
J Thorac Oncol. 2024;19:e11-e12.
PubMed

CHO MH, Cho JH, Shin DW
In Response.
J Thorac Oncol. 2024;19:e10.
PubMed

RICCIUTI B, Garassino MC
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
J Thorac Oncol. 2024;19:877-882.
PubMed

DICKHOFF C, Heineman DJ, van Dorp M, Senan S, et al
The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard.
J Thorac Oncol. 2024;19:862-865.
PubMed

UGALDE FIGUEROA P, Lacroix V, Van Schil PE
Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
J Thorac Oncol. 2024;19:858-861.
PubMed

LI MS, Ou SI
Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come.
J Thorac Oncol. 2024;19:855-857.
PubMed

PECCATORI FA, Florez N, Imbimbo M
From Approximation to Precision: Fertility and Pregnancy Questions in Young Patients With Lung Cancer.
J Thorac Oncol. 2024;19:852-854.
PubMed

May 2024

ROCCO G, Pennazza G, Tan KS, Vanstraelen S, et al
A real-world assessment of stage I lung cancer through electronic nose technology.
J Thorac Oncol. 2024 May 16:S1556-0864(24)00211.
PubMed Abstract available

BILLE A, Ripley RT, Giroux DJ, Gill RR, et al
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024 May 9:S1556-0864(24)00208.
PubMed Abstract available

NOWAK AK, Giroux DJ, Eisele M, Rosenthal A, et al
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.
J Thorac Oncol. 2024 May 9:S1556-0864(24)00207.
PubMed Abstract available

NASSAR AH, Kim SY, Adib E, Naqash AR, et al
Response letter by Nassar et al.
J Thorac Oncol. 2024;19:e7-e8.
PubMed

CHEN CY, Wang GS, Wei JC
Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
J Thorac Oncol. 2024;19:e6-e7.
PubMed

ZHAO B, Yao L, Ma W
Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
J Thorac Oncol. 2024;19:e5-e6.
PubMed

SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al
Lung Cancer in Brunei Darussalam.
J Thorac Oncol. 2024;19:698-705.
PubMed

LI Y, Adusumilli PS, Chou TY, Kadota K, et al
Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
J Thorac Oncol. 2024;19:677-697.
PubMed Abstract available

BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al
Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
J Thorac Oncol. 2024;19:671-676.
PubMed

SHIH JY
ERBB2 Amplification in NSCLC: How Many Faces?
J Thorac Oncol. 2024;19:668-670.
PubMed

ISHIKAWA S
Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
J Thorac Oncol. 2024;19:666-667.
PubMed

WOODARD GA, Dacic S
Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
J Thorac Oncol. 2024;19:663-665.
PubMed

LUO J, Sanchez M, Lee E, Hertzler H, et al
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
J Thorac Oncol. 2024;19:829-838.
PubMed Abstract available

OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al
Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
J Thorac Oncol. 2024;19:706-718.
PubMed Abstract available

April 2024

GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al
Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169.
PubMed Abstract available

ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
PubMed Abstract available

HORNE A, Harada K, Brown KD, Chua KLM, et al
Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
PubMed Abstract available

KIM IH, Lee GD, Choi S, Kim HR, et al
Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
PubMed Abstract available

SHUKLA V, Wang H, Varticovski L, Baek S, et al
Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
PubMed Abstract available

DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al
The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9(th)) Edition of the TNM Classification of Lung Cancer.
J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129.
PubMed Abstract available

CHANG CL, Lin KC, Chen WM, Shia BC, et al
Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
J Thorac Oncol. 2024;19:e2-e4.
PubMed

CHIOU CC, Lai TY
Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
J Thorac Oncol. 2024;19:e1-e2.
PubMed

SMESSEIM I, Baas P
Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
J Thorac Oncol. 2024;19:547-550.
PubMed

GRAY SG, Meirson T, Mutti L
Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
J Thorac Oncol. 2024;19:541-546.
PubMed

SAIFO M, Alali M, Alhabeb H, Awak M, et al
Lung Cancer in Syria.
J Thorac Oncol. 2024;19:534-540.
PubMed

SHOENBILL KA, Goldstein AO
Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
J Thorac Oncol. 2024;19:531-533.
PubMed

ZHU Z, Chen H
Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
J Thorac Oncol. 2024;19:528-530.
PubMed

LEE JB, Nagasaka M
Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
J Thorac Oncol. 2024;19:525-527.
PubMed

LEONG TL, McWilliams A, Wright GM
Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
J Thorac Oncol. 2024;19:522-524.
PubMed

DWYER LJ, Singhal N, Yu B, Kao S, et al
Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
J Thorac Oncol. 2024;19:650-652.
PubMed Abstract available

RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
J Thorac Oncol. 2024;19:626-635.
PubMed Abstract available

MCNAMEE N, Harvey C, Gray L, Khoo T, et al
Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
J Thorac Oncol. 2024;19:636-642.
PubMed Abstract available

NEL AE, Pavlisko EN, Roggli VL
The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
J Thorac Oncol. 2024;19:551-564.
PubMed Abstract available

March 2024

TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al
The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carci
J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122.
PubMed Abstract available

BORGEAUD M, Parikh K, Banna GL, Kim F, et al
Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123.
PubMed Abstract available

HINES JB, Cameron RB, Esposito A, Kim L, et al
Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.
J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
PubMed Abstract available

CHENG Y, Fan Y, Zhao Y, Huang D, et al
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
PubMed Abstract available

RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
PubMed Abstract available

KIM BG, Yoon S, Lee SY, Sohn JW, et al
How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
J Thorac Oncol. 2024;19:509-510.
PubMed

WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
Lung Cancer in Switzerland.
J Thorac Oncol. 2024;19:385-394.
PubMed

TEN HAAF K
Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
J Thorac Oncol. 2024;19:373-375.
PubMed

LI CP, Tsai RY, Chang HC, Gau SY, et al
Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:507-508.
PubMed

CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:380-384.
PubMed

LIM SM, Lee JB, Cho BC
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:376-379.
PubMed

YALAMANCHALI A, Hassan KA
MUC1-C: The Occam Razor of Osimertinib Resistance?
J Thorac Oncol. 2024;19:370-372.
PubMed

DAMMEIJER F, Dumoulin DW, Aerts JGJV
Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
J Thorac Oncol. 2024;19:366-369.
PubMed

CANI M, Novello S, Bironzo P
Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.
J Thorac Oncol. 2024;19:363-365.
PubMed

BORCZUK AC
Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.
J Thorac Oncol. 2024;19:360-362.
PubMed

YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
J Thorac Oncol. 2024;19:409-424.
PubMed Abstract available

February 2024

FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
PubMed Abstract available

ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
PubMed Abstract available

TORASAWA M, Horinouchi H
A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
J Thorac Oncol. 2024;19:351-352.
PubMed

NISHIMURA T
A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
J Thorac Oncol. 2024;19:350.
PubMed

HORITA N, Takase-Minegishi K
Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
J Thorac Oncol. 2024;19:348.
PubMed

CHANG HC, Gau SY
Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
J Thorac Oncol. 2024;19:346.
PubMed

YUAN C, Huang R, Wang Y
An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
J Thorac Oncol. 2024;19:344-345.
PubMed

BERMAS BL, Gerber DE
The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
J Thorac Oncol. 2024;19:196-198.
PubMed

VOKES EE, Mornex F, Sezer A, Cheng Y, et al
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
J Thorac Oncol. 2024;19:285-296.
PubMed Abstract available

REMON J, Saw SPL, Cortiula F, Singh PK, et al
Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
J Thorac Oncol. 2024;19:199-215.
PubMed Abstract available

DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
J Thorac Oncol. 2024;19:273-284.
PubMed Abstract available

OWONIKOKO TK
SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
J Thorac Oncol. 2024;19:193-195.
PubMed

LE X
Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
J Thorac Oncol. 2024;19:190-192.
PubMed

LEE JH
Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
J Thorac Oncol. 2024;19:187-189.
PubMed

SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
J Thorac Oncol. 2024;19:337-343.
PubMed Abstract available

January 2024

SHI Y, Hu X, Li X, Gong C, et al
Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
PubMed Abstract available

SHI Y, Chen J, Yang R, Wu H, et al
Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
PubMed Abstract available

NASSAR AH, Kim SY, Aredo JV, Feng J, et al
Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
PubMed Abstract available

SIMONS E, Camidge DR
Lung cancer oncogene-directed therapy, fertility and pregnancy.
J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
PubMed Abstract available

YU S, Feng J
Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
J Thorac Oncol. 2024;19:173-174.
PubMed

TANIZAKI J, Hayashi H
Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
J Thorac Oncol. 2024;19:15-17.
PubMed

BATAH H, Majeed Z, Moudgil R
Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
J Thorac Oncol. 2024;19:13-14.
PubMed

SINGHAL S, Gandara D, Riess JW
Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
J Thorac Oncol. 2024;19:10-12.
PubMed

FANG W, Girard N, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2024;19:52-70.
PubMed Abstract available

CHEN MF, Harada G, Liu D, DeMatteo R, et al
Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
J Thorac Oncol. 2024;19:153-159.
PubMed Abstract available

UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
J Thorac Oncol. 2024;19:106-118.
PubMed Abstract available

HAMADA A, Suda K, Nishino M, Obata K, et al
Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
J Thorac Oncol. 2024;19:71-79.
PubMed Abstract available

LAM S, Wynes MW, Connolly C, Ashizawa K, et al
The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
J Thorac Oncol. 2024;19:94-105.
PubMed Abstract available

TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
J Thorac Oncol. 2024;19:166-172.
PubMed Abstract available

December 2023

YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
PubMed Abstract available

ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
PubMed Abstract available

BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
PubMed Abstract available

VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
PubMed Abstract available

LI W, Fei K, Guo L, Wang Y, et al
CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
PubMed Abstract available

DACIC S, Travis WD, Giltnane JM, Kos F, et al
Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
PubMed Abstract available

XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
Lung Cancer in Albania.
J Thorac Oncol. 2023;18:1632-1637.
PubMed

FERREIRA M, Redman MW, Reckamp KL
Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
J Thorac Oncol. 2023;18:1629-1631.
PubMed

LI Z, Lu S
Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
J Thorac Oncol. 2023;18:1625-1628.
PubMed

MAKAREM M, Rotow JK
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
J Thorac Oncol. 2023;18:1615-1617.
PubMed

RUFFINI E, Huang J, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023;18:1655-1671.
PubMed Abstract available

MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
J Thorac Oncol. 2023;18:1672-1688.
PubMed Abstract available

OKUMURA M, Marino M, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023;18:1638-1654.
PubMed Abstract available

ANG YLE, Soo RA
Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
J Thorac Oncol. 2023;18:1621-1624.
PubMed

MEDINA CG, Xu Y, Ripley RT
International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
J Thorac Oncol. 2023;18:1618-1620.
PubMed

SOO RA, Cho BC, Kim JH, Ahn MJ, et al
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
J Thorac Oncol. 2023;18:1756-1766.
PubMed Abstract available

WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
J Thorac Oncol. 2023;18:1689-1702.
PubMed Abstract available

November 2023

WANG K, Du R, Myall NJ, Lewis WE, et al
BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
PubMed Abstract available

O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
PubMed Abstract available

LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
PubMed Abstract available

LU C, Wei XW, Wang Z, Zhou Z, et al
Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
PubMed Abstract available

HENSCHKE C, Huber R, Jiang L, Yang D, et al
Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
PubMed Abstract available

GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
PubMed Abstract available

CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
PubMed Abstract available

YANG JJ, Wen W, Zahed H, Zheng W, et al
Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
PubMed Abstract available

KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
PubMed Abstract available

HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
PubMed Abstract available

HONG TH, Hwang S, Cho J, Choi YL, et al
Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
PubMed Abstract available

QIU Z, Huang H, Zhang Y, Chen D, et al
Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
J Thorac Oncol. 2023;18:e138-e139.
PubMed

LI A, Yang Y, Zhang L, Hong S, et al
STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
J Thorac Oncol. 2023;18:e135-e138.
PubMed

AMORI G, Sugawara E, Inamura K
Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
J Thorac Oncol. 2023;18:e134-e135.
PubMed

CHEN WM, Yu YH, Chen M, Shia BC, et al
Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
J Thorac Oncol. 2023;18:e132-e134.
PubMed

ZHANG Y, Dai K, He D, Chen Z, et al
The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
J Thorac Oncol. 2023;18:e130-e131.
PubMed

NIU Y, Yao F, Yang H
"Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
J Thorac Oncol. 2023;18:e126-e128.
PubMed

MARTI JLG, Wells JZ, Wells A
Statins as a Secondary Preventive Agent for Metastatic Cancer.
J Thorac Oncol. 2023;18:e125-e126.
PubMed

OKONTA KE, Baiyewu LA, Jimoh MA
Lung Cancer in Nigeria.
J Thorac Oncol. 2023;18:1446-1457.
PubMed

DAGOGO-JACK I
We Don't Talk (Enough) About BRAF.
J Thorac Oncol. 2023;18:1443-1445.
PubMed

LEE JB, Ou SI
Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
J Thorac Oncol. 2023;18:1434-1442.
PubMed

HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
J Thorac Oncol. 2023;18:1431-1433.
PubMed

SOZZI G, Pastorino U
Small RNAs Do It Better.
J Thorac Oncol. 2023;18:1428-1430.
PubMed

YANKELEVITZ DF, Yip R, Henschke CI
Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
J Thorac Oncol. 2023;18:1426-1427.
PubMed

SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
J Thorac Oncol. 2023;18:1538-1549.
PubMed Abstract available

AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
J Thorac Oncol. 2023;18:1594-1606.
PubMed Abstract available

October 2023

WANG L, Luo Y, Ren S, Zhang Z, et al
A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
PubMed Abstract available

HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
PubMed Abstract available

CHO MH, Cho JH, Eun Y, Han K, et al
Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
PubMed Abstract available

STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
PubMed Abstract available

HENSCHKE CI, Yip R, Sun Q, Li P, et al
Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
PubMed Abstract available

ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
PubMed Abstract available

TRIPHURIDET N, Gao Y, Ou SI
Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
J Thorac Oncol. 2023;18:e122-e123.
PubMed

JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
J Thorac Oncol. 2023;18:e118-e122.
PubMed

CHOUR A, Duruisseaux M
Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
J Thorac Oncol. 2023;18:e114-e115.
PubMed

DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
J Thorac Oncol. 2023;18:1258-1260.
PubMed

INAMURA K
Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
J Thorac Oncol. 2023;18:e109-e110.
PubMed

ADJEI AA
The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
J Thorac Oncol. 2023;18:1257.
PubMed

HOE HJ, Balasubramanian A, John T
LASERing FLAURAL Arrangements in Asian EGFR Subsets.
J Thorac Oncol. 2023;18:1261-1264.
PubMed

REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
J Thorac Oncol. 2023;18:1351-1361.
PubMed Abstract available

PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
J Thorac Oncol. 2023;18:1362-1385.
PubMed Abstract available

GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
J Thorac Oncol. 2023;18:e112-e113.
PubMed

CHEN WM, Yu YH, Chen M, Shia BC, et al
Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
J Thorac Oncol. 2023;18:e107-e109.
PubMed

LIN TA, Chen SY, Chang R, Sun CK, et al
Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
J Thorac Oncol. 2023;18:e105-e106.
PubMed

WRIGHT K, Digby GC, Gyawali B, Jad R, et al
Malignant Superior Vena Cava Syndrome: A Scoping Review.
J Thorac Oncol. 2023;18:1268-1276.
PubMed Abstract available

September 2023

DUAN J, Wu L, Yang K, Zhao J, et al
Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
PubMed Abstract available

RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
PubMed Abstract available

JIANG C, Zhang Y, Fu F, Deng P, et al
A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
PubMed Abstract available

TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
PubMed Abstract available

WANG X, Bai H, Zhang J, Wang Z, et al
Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
PubMed Abstract available

FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
PubMed Abstract available

ZHANG S, Liu L, Shi S, He H, et al
Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
PubMed Abstract available

DINGEMANS AC, Mathijssen RHJ, van Rossum EFC
Approach to Alectinib-Induced Body Weight Gain in Patients With ALK+ Non-Small Lung Cancer.
J Thorac Oncol. 2023;18:e99-e100.
PubMed

LEE ATM, Ou SI, Lisberg A
Letter to Editor. Re "de Leeuw SP, et al. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK Positive Lung Cancer," Semaglutide a Potential Treatment for Serious Weight Gain From ALK Tyrosine Kinase Inhibitors?
J Thorac Oncol. 2023;18:e97-e99.
PubMed

GARCIA-PARDO M, Liu G
Re: Response to Letter to the Editor "Respiratory and Cardiometabolic Comorbidities and Stage I-III Non-Small Cell Lung Cancer (NSCLC) Survival: A Pooled Analysis From the International Lung Cancer Consortium".
J Thorac Oncol. 2023;18:e96-e97.
PubMed

ZHANG Y, Zhang J
Comment on "Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium".
J Thorac Oncol. 2023;18:e95-e96.
PubMed

FUJITA T, Amano H, Nakamura M, Hirano S, et al
Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1.
J Thorac Oncol. 2023;18:e93-e94.
PubMed

PONVILAWAN B, Sharma P, Mahadevia H, Subramanian J, et al
Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials.
J Thorac Oncol. 2023;18:e90-e93.
PubMed

HONG TH, Bang YH, Joe C, Choi YL, et al
Comment on "Leveraging NGS Data to Refine Immunotherapy Response Prediction in NSCLC: PD-L1 Copy Number, Tumor Mutation Burden, and Beyond".
J Thorac Oncol. 2023;18:e88-e90.
PubMed

INAMURA K
Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond.
J Thorac Oncol. 2023;18:e87-e88.
PubMed

PAZ-ARES LG, Carbone DP
Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA".
J Thorac Oncol. 2023;18:e102-e103.
PubMed

ZHAO B, Ma W
First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA.
J Thorac Oncol. 2023;18:e101-e102.
PubMed

ASMARA OD, Tenda ED, Singh G, Pitoyo CW, et al
Lung Cancer in Indonesia.
J Thorac Oncol. 2023;18:1134-1145.
PubMed

MOGHANAKI D, Lisberg A, Oh S, Lee JM, et al
Unresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection.
J Thorac Oncol. 2023;18:1129-1133.
PubMed

DICKHOFF C, Heineman DJ, Bahce I, Senan S, et al
Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment.
J Thorac Oncol. 2023;18:1124-1128.
PubMed

DENIZE T, Mino-Kenudson M
"Normal" Is Not Normal: The Role of the Immune Microenvironment of Adjacent Non-Neoplastic Tissue in Dictating the Biology of Early-Stage NSCLC.
J Thorac Oncol. 2023;18:1121-1123.
PubMed

FACCHINETTI F, Janne PA, Tiseo M
Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era.
J Thorac Oncol. 2023;18:1118-1120.
PubMed

SCHROEDER BA, Thomas A
SCLC Subtypes and Biomarkers of the Transformative Immunotherapy Responses.
J Thorac Oncol. 2023;18:1114-1117.
PubMed

CORNO C, Beretta GL, Perego P
Concomitant Targeting of MDM2 and MEK: A New Translatable Combinatorial Strategy?
J Thorac Oncol. 2023;18:1111-1113.
PubMed

OPITZ I, Bille A, Dafni U, Nackaerts K, et al
European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database.
J Thorac Oncol. 2023;18:1233-1247.
PubMed Abstract available

FARINEA G, Crespi V, Listi A, Righi L, et al
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
J Thorac Oncol. 2023;18:1146-1164.
PubMed Abstract available

ELKRIEF A, Odintsov I, Markov V, Caeser R, et al
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
J Thorac Oncol. 2023;18:1165-1183.
PubMed Abstract available

August 2023

CHO BC, Lee JS, Wu YL, Cicin I, et al
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial.
J Thorac Oncol. 2023 Aug 17:S1556-0864(23)00738.
PubMed Abstract available

IMBODY D, Arce K, Solanki HS, Haura EB, et al
Targeting SHP2 Signaling in Lung Cancer.
J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00729.
PubMed

LI Y, Juergens RA, Finley C, Swaminath A, et al
Moving Through Inertia - The Promise of Current and Future Treatment Options in the Management of Stage III Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00731.
PubMed Abstract available

CHIH-HSIN YANG J, Liu G, Lu S, He J, et al
Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
J Thorac Oncol. 2023 Aug 11:S1556-0864(23)00730.
PubMed Abstract available

LARA-MEJIA L, Cardona AF, Mas L, Martin C, et al
Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer.
J Thorac Oncol. 2023 Aug 10:S1556-0864(23)00727.
PubMed Abstract available

In the published article titled "New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study", J Thorac Oncol 2019 Jan;15(1):125-129.
J Thorac Oncol. 2023 Aug 9:S1556-0864(23)00675.
PubMed

XIE H, Dai C, Gu C, Zhao S, et al
Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification to Upgrade Extracapsular Extension of Tumor in Nodes From R0 to Incomplete Resection.
J Thorac Oncol. 2023 Aug 9:S1556-0864(23)00723.
PubMed Abstract available

DACIC S, Travis W, Redman M, Saqi A, et al
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
PubMed Abstract available

BEARZ A, Martini JF, Jassem J, Kim SW, et al
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations.
J Thorac Oncol. 2023 Aug 2:S1556-0864(23)00691.
PubMed Abstract available

KUS T, Aktas G
In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
J Thorac Oncol. 2023;18:e83-e84.
PubMed

CONTRUCCI RR, Ter Heine R, Hendriks LEL, de Rouw N, et al
Folinic Acid to Prevent Pemetrexed-Associated Neutropenia After Intrathecal Administration: A Quick Win.
J Thorac Oncol. 2023;18:e81-e82.
PubMed

AKINBOBOLA O, Ray MA, Smeltzer MP, Osarogiagbon RU, et al
In Response: Taichiro Goto "Kit Use May Not Be Key To Improved Prognosis"; Response to "Akinbobola O, Ray MA, Fehnel C, et al. Institution-Level Evolution of Lung Cancer Resection Quality With Implementation of a Lymph Node Specimen Collection Kit".
J Thorac Oncol. 2023;18:e80-e81.
PubMed

GOTO T
Kit Use May Not Be Key to Improved Prognosis.
J Thorac Oncol. 2023;18:e79-e80.
PubMed

VIDETIC GMM
Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Become the Standard of Care.
J Thorac Oncol. 2023;18:986-989.
PubMed

MACBETH F, Treasure T
Local Treatments of Oligometastatic and Oligoprogressive NSCLC Should Not Become the Standard of Care.
J Thorac Oncol. 2023;18:981-985.
PubMed

ISLAM MR, Siddiqua SM, Islam R, Hossain A, et al
Lung Cancer in Bangladesh.
J Thorac Oncol. 2023;18:972-980.
PubMed

TAORMINA JM, Camidge DR
Editorial Related to Leeuw et al.: The Evolution of Expectations: How Our Views On "Acceptable" Toxicities Are Changing With Prolonged Lung Cancer Treatments.
J Thorac Oncol. 2023;18:967-969.
PubMed

BORM FJ, Smit EF
Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
J Thorac Oncol. 2023;18:964-966.
PubMed

NORRIS RP, Dew R, Greystoke A, Todd A, et al
Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System.
J Thorac Oncol. 2023;18:990-1002.
PubMed Abstract available

PROTO C, Manglaviti S, Lo Russo G, Musca M, et al
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
J Thorac Oncol. 2023;18:1070-1081.
PubMed Abstract available

CHEN WM, Yu YH, Chen M, Shia BC, et al
Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
J Thorac Oncol. 2023;18:1082-1093.
PubMed Abstract available

LIN SH
Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
J Thorac Oncol. 2023;18:970-971.
PubMed

July 2023

LI A, Wang Y, Yu Z, Tan Z, et al
STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/IFN-I/CD8(+) T cell Dysfunction in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00688.
PubMed Abstract available

RIMNER A, Ruffini E, Cilento V, Goren E, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
PubMed Abstract available

LAM S, Bai C, Baldwin D, Chen Y, et al
Current and Future Perspectives on CT Screening for Lung Cancer: A Road Map for 2023-2027 from the IASLC.
J Thorac Oncol. 2023 Jul 22:S1556-0864(23)00687.
PubMed Abstract available

AROLT C, Dugan M, Wild R, Richartz V, et al
KEAP1/NFE2L2 pathway signature outperforms KEAP1/NFE2L2 mutation status and reveals alternative pathway-activating mutations in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Jul 18:S1556-0864(23)00684.
PubMed Abstract available

LEE JM, McNamee CJ, Toloza E, Negrao MV, et al
Neoadjuvant Targeted Therapy in Resectable Non-Small Cell Lung Cancer: Current and Future Perspectives.
J Thorac Oncol. 2023 Jul 12:S1556-0864(23)00671.
PubMed Abstract available

SIKOSEK T, Horos R, Trudzinski F, Jehn J, et al
Early Detection of Lung Cancer using small RNAs.
J Thorac Oncol. 2023 Jul 10:S1556-0864(23)00670.
PubMed Abstract available

RIEDEL R, Fassunke J, Scheel AH, Scheffler M, et al
Brief Report: MET fusions in Non-small cell lung cancer: Clinicopathologic features and response to MET inhibition.
J Thorac Oncol. 2023 Jul 8:S1556-0864(23)00666.
PubMed Abstract available

EVANS WK, Tammemagi MC, Walker MJ, Cameron E, et al
Integrating smoking cessation into LDCT lung cancer screening: Results of the Ontario, Canada Pilot.
J Thorac Oncol. 2023 Jul 6:S1556-0864(23)00669.
PubMed Abstract available

WANG CL, Hsu KH, Chang YH, Ho CC, et al
Low-dose CT screening in relatives with a family history of lung cancer.
J Thorac Oncol. 2023 Jul 4:S1556-0864(23)00639.
PubMed Abstract available

KEOGH RJ, Barr MP, Keogh A, McMahon D, et al
Lung Cancer in the Republic of Ireland.
J Thorac Oncol. 2023;18:851-857.
PubMed

DOWLATI A, Towe CW, Linden PA
Who Are You "KITTING"? The Use of Kits to Collect Lymph Nodes During Lung Cancer Surgery.
J Thorac Oncol. 2023;18:838-840.
PubMed

CHOE JK, Li Y, Adusumilli PS
Response to Letter to the Editor: "Which Percentage of Micropapillary and Solid Histological Patterns in Lymph Node Metastases Is Significantly Associated With Poor Outcomes?".
J Thorac Oncol. 2023;18:e76-e77.
PubMed

NIU Y, He Y, Li Z
Which Percentage of Micropapillary and Solid Histologic Patterns in Lymph Node Metastases Is Significantly Associated With Poor Outcomes?
J Thorac Oncol. 2023;18:e75-e76.
PubMed

ZHAO B, Qi H, Wu J, Ma W, et al
Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol. 2023;18:e72-e73.
PubMed

KUNIMASA K, Wada M, Nishino K
Severe Psychosis Associated With Lorlatinib.
J Thorac Oncol. 2023;18:e71-e72.
PubMed

NADRES B, Momcilovic M, Shackelford DB, Lisberg A, et al
An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors.
J Thorac Oncol. 2023;18:847-850.
PubMed

NORMAN A, Adjei AA
Expanding the KRASG12C Inhibitor Class: What Do We Need Next?
J Thorac Oncol. 2023;18:844-846.
PubMed

COOPER WA, John T
Rethinking Biomarkers for Combination Chemoimmunotherapy.
J Thorac Oncol. 2023;18:841-843.
PubMed

KIM HK
Selective Mediastinal Lymph Node Dissection: Precision Surgery in the Era of Precision Medicine.
J Thorac Oncol. 2023;18:834-837.
PubMed

MINCHOM A, Popat S
Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?
J Thorac Oncol. 2023;18:830-833.
PubMed

LAU BC, Wu YF, No HJ, Ko RB, et al
Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Antiangiogenic Agents.
J Thorac Oncol. 2023;18:922-930.
PubMed Abstract available

SUN D, Liu J, Zhou H, Shi M, et al
Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC.
J Thorac Oncol. 2023;18:869-881.
PubMed Abstract available

June 2023

GILLESPIE CS, Mustafa MA, Richardson GE, Alam AM, et al
Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis.
J Thorac Oncol. 2023 Jun 29:S1556-0864(23)00638.
PubMed Abstract available

CHI-LEUNG LAM D, Liam CK, Andarini S, Park S, et al
Lung Cancer Screening in Asia: An Expert Consensus Report.
J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00635.
PubMed Abstract available

PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
PubMed Abstract available

HARATANI K, Nakamura A, Mamesaya N, Mitsuoka S, et al
Tumor microenvironment landscape of non-small cell lung cancer reveals resistance mechanisms for PD-L1 blockade following chemoradiotherapy: a multi-center prospective biomarker study (WJOG11518L/SUBMARINE).
J Thorac Oncol. 2023 Jun 24:S1556-0864(23)00633.
PubMed Abstract available

JUNG HA, Ku BM, Kim YJ, Park S, et al
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stage I-IIIA EGFR Mutant-Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Jun 10:S1556-0864(23)00607.
PubMed Abstract available

SOO RA, Martini JF, van der Wekken AJ, Teraoka S, et al
Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive non-small cell lung cancer.
J Thorac Oncol. 2023 Jun 7:S1556-0864(23)00580.
PubMed Abstract available

BERG CD, Schiller JH, Boffetta P, Cai J, et al
AIR POLLUTION AND LUNG CANCER A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee.
J Thorac Oncol. 2023 Jun 3:S1556-0864(23)00601.
PubMed Abstract available

PICCIRILLO MC, Chu Q, Bradbury P, Seymour L, et al
Response to a Letter Received Entitled: "'Brief Report: Canadian Cancer Trials Group IND.227': Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma".
J Thorac Oncol. 2023;18:e68-e69.
PubMed

GEMELLI M
"Brief Report: Canadian Cancer Trials Group IND.227": Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma.
J Thorac Oncol. 2023;18:e67-e68.
PubMed

NAKASHIMA K, Tsubata Y, Isobe T
Successful Pembrolizumab Rechallenge in a Patient With Advanced NSCLC After Pemetrexed-Induced Palm Pustules.
J Thorac Oncol. 2023;18:e66-e67.
PubMed

MA Z, Yang X, Hui Z
Association of Heart Base Dose With Overall Survival in Patients With NSCLC Undergoing Postoperative Radiotherapy.
J Thorac Oncol. 2023;18:e62-e64.
PubMed

ZHAO B, Wu J, Ma W
Clinical and Genomic Factors Predicting the Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
J Thorac Oncol. 2023;18:e59-e60.
PubMed

SMELTZER MP, Liao W, Osarogiagbon RU
In Response: Letter to the Editor: Re "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening".
J Thorac Oncol. 2023;18:e58-e59.
PubMed

TRIPHURIDET N, Ou SI
Reply to "Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol. 2023;18(2):158-168".
J Thorac Oncol. 2023;18:e57-e58.
PubMed

CARBONE M, Yang H, Pass HI, Taioli E, et al
Did the Ban on Asbestos Reduce the Incidence of Mesothelioma?
J Thorac Oncol. 2023;18:694-697.
PubMed

CHIU CH, Yang PC
Never Say No to Never-Smokers.
J Thorac Oncol. 2023;18:689-693.
PubMed

DELASOS L, Madabhushi A, Patil PD
Can Radiomics Bridge the Gap Between Immunotherapy and Precision Medicine in Lung Cancer?
J Thorac Oncol. 2023;18:686-688.
PubMed

LIM JH, Lee S, Ryu JS
Prediction of Treatment Response to Chemoimmunotherapy: Concerted Effort Needed.
J Thorac Oncol. 2023;18:682-685.
PubMed

ACKER F, Althoff FC, Sebastian M
Systemic Treatment for Brain Metastases in NSCLC: A New Chapter.
J Thorac Oncol. 2023;18:678-681.
PubMed

ROLFO C, Russo A
Exploiting the Full Potential of Novel Agents Targeting EGFR Exon 20 Insertions in Advanced NSCLC: Next-Generation Sequencing Outperforms Polymerase Chain Reaction-Based Testing.
J Thorac Oncol. 2023;18:674-677.
PubMed

MAKHARADZE T, Gogishvili M, Melkadze T, Baramidze A, et al
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol. 2023;18:755-768.
PubMed Abstract available

PICCIRILLO MC, Chu Q, Bradbury P, Tu W, et al
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
J Thorac Oncol. 2023;18:813-819.
PubMed Abstract available

HUANG J, Chan SC, Pang WS, Chow SH, et al
Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study.
J Thorac Oncol. 2023;18:792-802.
PubMed Abstract available

May 2023

ALESSI JV, Wang X, Elkrief A, Ricciuti B, et al
Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in non-small cell lung cancer.
J Thorac Oncol. 2023 May 27:S1556-0864(23)00578.
PubMed Abstract available

JOHN T, Grohe C, Goldman JW, Shepherd FA, et al
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB-IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial.
J Thorac Oncol. 2023 May 24:S1556-0864(23)00574.
PubMed Abstract available

CHOUR A, Denis J, Mascaux C, Zysman M, et al
Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRAS(G12C)-mutant lung cancer.
J Thorac Oncol. 2023 May 20:S1556-0864(23)00572.
PubMed Abstract available

RUDIN CM, Balli D, Lai WV, Richards AL, et al
Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation.
J Thorac Oncol. 2023 May 18:S1556-0864(23)00554.
PubMed Abstract available

CHENG C, Hong W, Li Y, Xiao X, et al
Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis.
J Thorac Oncol. 2023 May 5:S1556-0864(23)00527.
PubMed Abstract available

RECK M, Ciuleanu TE, Lee JS, Schenker M, et al
Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1.
J Thorac Oncol. 2023 May 3:S1556-0864(23)00525.
PubMed Abstract available

GARON EB, Spira AI, Goldberg SB, Chaft JE, et al
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in PD-(L)1-Monotherapy Pretreated, Advanced Non-Small Cell Lung Cancer: Results From a Phase 1b Clinical Trial.
J Thorac Oncol. 2023 May 3:S1556-0864(23)00524.
PubMed Abstract available

CHENG C, Nguyen TT, Tang M, Wang X, et al
Immune infiltration in tumor and adjacent non-neoplastic regions co-determines patient clinical outcomes in early-stage lung cancer.
J Thorac Oncol. 2023 May 3:S1556-0864(23)00526.
PubMed Abstract available

ZHOU F, Zhou C
Notch Mutations as a Novel Biomarker for Immunotherapy.
J Thorac Oncol. 2023;18:e54-e56.
PubMed

KUNIMASA K
Notch Mutations as a Novel Biomarker for Immunotherapy.
J Thorac Oncol. 2023;18:e53-e54.
PubMed

MURCIANO-GOROFF YR, Lin ST, Wilhelm C, Iasonos A, et al
In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC".
J Thorac Oncol. 2023;18:e52-e53.
PubMed

ZHAO B, Xing H, Ma W
Selpercatinib Controls Central Nervous System Disease in Patients With NSCLC With RET Fusion.
J Thorac Oncol. 2023;18:e51-e52.
PubMed

YANG CY, Lin YT, Lin LJ, Yang PC, et al
Response to Letter to the Editor: "Factors Other Than Low-Dose Computed Tomography Screening Related to Stage Shift and Improved Survival of Lung Cancer".
J Thorac Oncol. 2023;18:e49-e51.
PubMed

INAGAKI Y
Factors Other Than Low-Dose Computed Tomography Screening Related to Stage Shift and Improved Survival of Lung Cancer.
J Thorac Oncol. 2023;18:e48-e49.
PubMed

OKUBO Y, Yatabe Y
Reply to the Letter to the Editor From He Y et al.
J Thorac Oncol. 2023;18:e46-e48.
PubMed

HE Y, Zhang J, Li Z
The Protective and Risk Factors Affecting the Prognosis of Pathologic Stage IA Adenocarcinoma: How to Balance?
J Thorac Oncol. 2023;18:e45-e46.
PubMed

LAU SCM, Ou SI
Selpercatinib as the Guardian of the Central Nervous System for Patients With RET Fusion-Positive NSCLC?
J Thorac Oncol. 2023;18:561-563.
PubMed

NAKAJIMA J
Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis.
J Thorac Oncol. 2023;18:559-560.
PubMed

ERASMUS JJ, Vlahos I
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
J Thorac Oncol. 2023;18:556-558.
PubMed

HORINOUCHI H
Another Pirate in the Red Ocean? CD73-Targeted Therapy in EGFR-Mutated NSCLC.
J Thorac Oncol. 2023;18:552-555.
PubMed

SUN L, Marmarelis M, Aggarwal C
Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed?
J Thorac Oncol. 2023;18:549-551.
PubMed

NAIDOO J, Antonia S, Wu YL, Cho BC, et al
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
J Thorac Oncol. 2023;18:657-663.
PubMed Abstract available

MCWILLIAM A, Abravan A, Banfill K, Faivre-Finn C, et al
Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival.
J Thorac Oncol. 2023;18:599-607.
PubMed Abstract available

LI Y, Byun AJ, Choe JK, Lu S, et al
Micropapillary and Solid Histologic Patterns in N1 and N2 Lymph Node Metastases Are Independent Factors of Poor Prognosis in Patients With Stages II to III Lung Adenocarcinoma.
J Thorac Oncol. 2023;18:608-619.
PubMed Abstract available

ZHOU C, Chen G, Huang Y, Zhou J, et al
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
J Thorac Oncol. 2023;18:628-639.
PubMed Abstract available

GU Z, Hao X, Liu Y, Xu N, et al
Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis.
J Thorac Oncol. 2023;18:640-649.
PubMed Abstract available

April 2023

PARK CK, Oh HJ, Kim YC, Kim YH, et al
Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Durvalumab after Chemoradiotherapy: PACIFIC-KR.
J Thorac Oncol. 2023 Apr 19:S1556-0864(23)00495.
PubMed Abstract available

HONG TH, Bang YH, Joe C, Hwang S, et al
Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer.
J Thorac Oncol. 2023 Apr 5:S1556-0864(23)00482.
PubMed Abstract available

WANG Y, Che G
Authors' Reply to Letter to the Editor Regarding the Article "Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases".
J Thorac Oncol. 2023;18:e46-e47.
PubMed

WANG H, Yang R, Li W
Letter to the Editor Regarding the Article "Risk and Influencing Factors for Subsequent Primary Lung Cancer After Treatment of Breast Cancer: A Systematic Review and Two Meta-Analyses Based on Four Million Cases".
J Thorac Oncol. 2023;18:e44-e45.
PubMed

HAN DH, Duan F, Patz EF Jr
Response to Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions.
J Thorac Oncol. 2023;18:e41-e42.
PubMed

LI Z, He Y, Xiong Z
Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions.
J Thorac Oncol. 2023;18:e40-e41.
PubMed

GIRARD N, Garassino MC, Solomon B
Response to Letter to the Editor From Binghao Zhao et al.
J Thorac Oncol. 2023;18:e40-e41.
PubMed

ZHAO B, Li H, Ma W
Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study.
J Thorac Oncol. 2023;18:e38-e39.
PubMed

NG JKM, Chan CF, Li JJX
Thymic Carcinoma With Malignant Effusion-a Rare Cytologic and Radiologic Mimicker of Metastatic NSCLC.
J Thorac Oncol. 2023;18:e35-e37.
PubMed

CHEN CH, Hsu CK, Lee CN
Tepotinib-Induced Palmoplantar Keratoderma-Like Hand-Foot Skin Reaction.
J Thorac Oncol. 2023;18:e33-e34.
PubMed

ZOHRABYAN D, Karapetyan N, Danielyan S, Saghatelyan T, et al
Lung Cancer in Armenia.
J Thorac Oncol. 2023;18:402-409.
PubMed

EBI H
Drug-Tolerant Persister Cells After EGFR Tyrosine Kinase Inhibitor Treatment: Their Origin and the Influences From the Tumor Microenvironment.
J Thorac Oncol. 2023;18:399-401.
PubMed

MOREIRA AL, Sabari JK
Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures.
J Thorac Oncol. 2023;18:396-398.
PubMed

LAU SCM
The Value of Comprehensive Molecular Profiling in Early Stage Lung Cancer.
J Thorac Oncol. 2023;18:393-395.
PubMed

LE X
Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity.
J Thorac Oncol. 2023;18:390-392.
PubMed

VISCA P, Gallo E, Marino M
New Morphologic Findings Support Invasiveness Criteria in Small-Sized Nonmucinous Lepidic Adenocarcinoma: Commenting a Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
J Thorac Oncol. 2023;18:387-389.
PubMed

MOGHAL N, Li Q, Stewart EL, Navab R, et al
Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.
J Thorac Oncol. 2023;18:499-515.
PubMed Abstract available

THUNNISSEN E, Beasley MB, Borczuk A, Dacic S, et al
Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth: A Proposal by the International Association for the Study of Lung Cancer Pathology Committee.
J Thorac Oncol. 2023;18:447-462.
PubMed Abstract available

CHOUDHURY NJ, Marra A, Sui JSY, Flynn J, et al
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
J Thorac Oncol. 2023;18:463-475.
PubMed Abstract available

MUTHUSAMY B, Raskina K, Lofgren KT, Li G, et al
Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma.
J Thorac Oncol. 2023;18:476-486.
PubMed Abstract available

REMON J, Hendriks LEL, Mountzios G, Garcia-Campelo R, et al
MET alterations in NSCLC-Current Perspectives and Future Challenges.
J Thorac Oncol. 2023;18:419-435.
PubMed Abstract available

March 2023

DE LEEUW SP, Pruis MA, Sikkema BJ, Mohseni M, et al
Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer.
J Thorac Oncol. 2023 Mar 29:S1556-0864(23)00219.
PubMed Abstract available

ZHANG H, Nabel CS, Li D, O'Connor RI, et al
Histone deacetylase 6 inhibition exploits selective metabolic vulnerabilities in LKB1 mutant, KRAS driven non-small cell lung cancer.
J Thorac Oncol. 2023 Mar 21:S1556-0864(23)00197.
PubMed Abstract available

CORNELISSEN R, Prelaj A, Sun S, Baik C, et al
Poziotinib in Treatment-Naive Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4).
J Thorac Oncol. 2023 Mar 21:S1556-0864(23)00199.
PubMed Abstract available

LI Z, Song Z, Zhao Y, Wang P, et al
D-1553 (garsorasib), a Potent and Selective Inhibitor of KRAS(G12C) in Patients with Non-Small Cell Lung Cancer: Phase I Study Results.
J Thorac Oncol. 2023 Mar 20:S1556-0864(23)00196.
PubMed Abstract available

AKINBOBOLA O, Ray MA, Fehnel C, Saulsberry A, et al
Institution-Level Evolution of Lung Cancer Resection Quality with Implementation of a Lymph Node Specimen Collection Kit.
J Thorac Oncol. 2023 Mar 15:S1556-0864(23)00191.
PubMed Abstract available

ZHAO J, Zhao L, Guo W, Wang S, et al
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients with Resectable Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
J Thorac Oncol. 2023 Mar 2:S1556-0864(23)00161.
PubMed Abstract available

OU SI, Kim ES
Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
J Thorac Oncol. 2023;18:e30-e31.
PubMed

URBANSKA EM, Sorensen JB, Santoni-Rugiu E
Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
J Thorac Oncol. 2023;18:e28-e29.
PubMed

ZHAO B, Wu J, Ma W
Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib.
J Thorac Oncol. 2023;18:e26-e27.
PubMed

ZHANG R, Li Y, Chen F, Christiani DC, et al
Reply to Scott et al: "Gene-Gene interaction in ever-smokers with lung cancer: Is there confounding by COPD in GWAS?".
J Thorac Oncol. 2023;18:e24-e26.
PubMed

YOUNG RP, Scott RJ
Gene-Gene Interaction in Ever Smokers With Lung Cancer: Is There Confounding by Chronic Obstructive Pulmonary Disease in Genome-Wide Association Studies?
J Thorac Oncol. 2023;18:e23-e24.
PubMed

BORILOVA S, Dusek L, Jakubikova L, Turcani P, et al
Lung Cancer in the Czech Republic.
J Thorac Oncol. 2023;18:271-277.
PubMed

GIRARD N
In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50.
J Thorac Oncol. 2023;18:268-270.
PubMed

MARMARELIS ME, Sun L, Aggarwal C
Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor.
J Thorac Oncol. 2023;18:265-267.
PubMed

RAMELLA S, Soda P
Stage I Stereotactic Body Radiation Therapy Outcome's Prediction Models: Perfection Is the Enemy of Utility.
J Thorac Oncol. 2023;18:262-264.
PubMed

YEHIA L, Centomo ML, Pandolfi PP, Eng C, et al
Two's Company, Three's a Crowd: Rb1/Trp53/Pten Trifecta and Lung Cancer Molecular and Histopathologic Heterogeneity.
J Thorac Oncol. 2023;18:260-261.
PubMed

RODEN AC, Molina JR
Plasma Biomarkers to Monitor Bronchopulmonary Carcinoids-Are We There Yet?
J Thorac Oncol. 2023;18:257-259.
PubMed

FRANK MS, Bodtger U
An Individualized Approach to Comorbidities in Lung Cancer.
J Thorac Oncol. 2023;18:254-256.
PubMed

KATZ SI, Straus CM, Roshkovan L, Blyth KG, et al
Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group.
J Thorac Oncol. 2023;18:278-298.
PubMed Abstract available

NISMAN B, Oleinikov K, Nechushtan H, Maimon O, et al
Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report.
J Thorac Oncol. 2023;18:369-376.
PubMed Abstract available

ZHANG L, Liu C, Zhang B, Zheng J, et al
PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion.
J Thorac Oncol. 2023;18:324-338.
PubMed Abstract available

FALKSON CB, Vella ET, Ellis PM, Maziak DE, et al
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review.
J Thorac Oncol. 2023;18:299-312.
PubMed Abstract available

February 2023

HE K, Berz D, Gadgeel SM, Iams WT, et al
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.
J Thorac Oncol. 2023 Feb 24:S1556-0864(23)00158.
PubMed Abstract available

ZHANG Y, Deng C, Zheng Q, Qian B, et al
Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: A prospective, multicenter, clinical trial.
J Thorac Oncol. 2023 Feb 23:S1556-0864(23)00138.
PubMed Abstract available

ALESSI JV, Elkrief A, Ricciuti B, Wang X, et al
Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced non-small cell lung cancer (NSCLC).
J Thorac Oncol. 2023 Feb 10:S1556-0864(23)00121.
PubMed Abstract available

TRIPHURIDET N, Zhang SS, Nagasaka M, Gao Y, et al
Low dose computed tomography (LDCT) screening in Asian female never-smokers is as efficacious in detecting lung cancer as in Asian male-ever-smokers: a systematic review and meta-analysis.
J Thorac Oncol. 2023 Feb 10:S1556-0864(23)00124.
PubMed Abstract available

CHEN M, Lu H, Copley SJ, Han Y, et al
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity from Programmed Cell Death-1 Pathway Inhibition in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2023 Feb 9:S1556-0864(23)00096.
PubMed Abstract available

ASAMURA H, Nishimura KK, Giroux DJ, Chansky K, et al
IASLC lung cancer staging project: the new database to inform revisions in the ninth edition of the TNM classification of lung cancer.
J Thorac Oncol. 2023 Feb 9:S1556-0864(23)00097.
PubMed Abstract available

IGNATIUS OU SH, Hong JL, Christopoulos P, Lin HM, et al
Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non-small Cell Lung Cancer.
J Thorac Oncol. 2023 Feb 2:S1556-0864(23)00095.
PubMed Abstract available

HOU X, Zhou C, Wu G, Lin W, et al
Efficacy, Safety, and Health-Related Quality of Life with Camrelizumab Plus Pemetrexed and Carboplatin as First-Line treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Brain Metastases (CAP-BRAIN): A Multicentre, Open-Label, Single-Ar
J Thorac Oncol. 2023 Feb 2:S1556-0864(23)00092.
PubMed Abstract available

PROVENZANO L, Damian S, Duca M, Della Valle S, et al
Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach.
J Thorac Oncol. 2023;18:e9-e10.
PubMed

HEIDEN BT, Puri V
Response to "Which Factors Determinate the Lymphadenectomy Definition?".
J Thorac Oncol. 2023;18:e8-e9.
PubMed

CHIAPPETTA M, Sassorossi C, Lococo F, Margaritora S, et al
Which Factors Determinate the Lymphadenectomy Definition? Comment on "Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early-Stage Non-Small Cell Lung Cancer".
J Thorac Oncol. 2023;18:e7-e8.
PubMed

ZHANG L, Yang X
Comment on: "Quitting Smoking at or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis".
J Thorac Oncol. 2023;18:e17-e19.
PubMed

HIGASHIYAMA RI, Yoshida T, Yagishita S, Hamada A, et al
In Response: Letter Received From Dr. Charles Ricordel Titled "Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC".
J Thorac Oncol. 2023;18:e16-e17.
PubMed

PIERRE C, Goter T, Lena H, Le Guen Y, et al
Safety of Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors for Advanced NSCLC.
J Thorac Oncol. 2023;18:e14-e16.
PubMed

DE CARLO E, Bertoli E, Chimienti E, Del Conte A, et al
Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC.
J Thorac Oncol. 2023;18:e11-e13.
PubMed

ARTAL-CORTES AF, Verdun-Aguilar J, Marquez-Medina D
Opening Windows for Thymic Tumors.
J Thorac Oncol. 2023;18:136-138.
PubMed

O'LEARY C, Naidoo J
PACIFIC in the Real World.
J Thorac Oncol. 2023;18:133-135.
PubMed

TAN WL, Lim DW
Is There a Unicorn Among the Uncommon EGFR Mutations?
J Thorac Oncol. 2023;18:129-132.
PubMed

NAGASAKA M, Ou SI
CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib?
J Thorac Oncol. 2023;18:139-142.
PubMed

LARSON NB, Oberg AL, Adjei AA, Wang L, et al
A Clinician's Guide to Bioinformatics for Next-Generation Sequencing.
J Thorac Oncol. 2023;18:143-157.
PubMed Abstract available

MERBOTH F, Nebelung H, Wotschel N, Liebscher H, et al
Robotic Esophagectomy Compared With Open Esophagectomy Reduces Sarcopenia within the First Postoperative Year: A Propensity Score-Matched Analysis.
J Thorac Oncol. 2023;18:232-244.
PubMed Abstract available

JUNG HA, Kim M, Kim HS, Kim JH, et al
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21).
J Thorac Oncol. 2023;18:223-231.
PubMed Abstract available

BAR J, Peled N, Schokrpur S, Wolner M, et al
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
J Thorac Oncol. 2023;18:169-180.
PubMed Abstract available

GIRARD N, Bar J, Garrido P, Garassino MC, et al
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
J Thorac Oncol. 2023;18:181-193.
PubMed Abstract available

YAN W, Zhong WZ, Liu YH, Chen Q, et al
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial.
J Thorac Oncol. 2023;18:194-203.
PubMed Abstract available

January 2023

KILLINGBERG KT, Gronberg BH, Slaaen M, Kirkevold O, et al
Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited stage small-cell lung cancer.
J Thorac Oncol. 2023 Jan 27:S1556-0864(23)00016.
PubMed Abstract available

MURCIANO-GOROFF YR, Falcon CJ, Lin ST, Chacko C, et al
Original article: Central nervous system disease in patients with RET fusion-positive non-small cell lung cancer treated with selpercatinib.
J Thorac Oncol. 2023 Jan 16:S1556-0864(23)00008.
PubMed Abstract available

ALDEA M, Marinello A, Duruisseaux M, Zrafi W, et al
RET-MAP: An international multi-center study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion.
J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01994.
PubMed Abstract available

DERCLE L, Fronheiser M, Rizvi NA, Hellmann MD, et al
Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer.
J Thorac Oncol. 2023 Jan 13:S1556-0864(22)01995.
PubMed Abstract available

YANKELEVITZ DF, Yip R, Henschke CI
Impact of Duration of Diagnostic Workup on Prognosis for Early Lung Cancer.
J Thorac Oncol. 2023 Jan 12:S1556-0864(22)01996.
PubMed Abstract available

KIM DW, Kim SW, Camidge DR, Shu CA, et al
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report.
J Thorac Oncol. 2023 Jan 11:S1556-0864(22)01997.
PubMed Abstract available

KENMOTSU H, Mori K, Nakagawa K, Yamamoto N, et al
Response to "Letter to the Editor" From David Y. Mak et al.
J Thorac Oncol. 2023;18:e4-e5.
PubMed

MAK DY, Tjong MC, Louie AV
Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations.
J Thorac Oncol. 2023;18:e3-e4.
PubMed

ZHAO B, Li H, Wu J, Ma W, et al
Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial.
J Thorac Oncol. 2023;18:e1-e2.
PubMed

AHN JY, Nagasaka M
Neptune, the Next Pluto?-Durvalumab and Tremelimumab Face Challenges in Entering the NSCLC Space.
J Thorac Oncol. 2023;18:29-30.
PubMed

JIA K, Ren S
Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction?
J Thorac Oncol. 2023;18:26-28.
PubMed

OEZKAN F, Seweryn M, Shukuya T, Owen DH, et al
Improvement in Survival for Patients With Lung Cancer in Taiwan: Implications and Call to Action.
J Thorac Oncol. 2023;18:21-25.
PubMed

FERRARA R, Ricciuti B, Ambrogio C, Trapani D, et al
The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers.
J Thorac Oncol. 2023;18:17-20.
PubMed

COLORI A, Hiley C
The Interaction of Preexisting Cardiac Dysfunction and Heart Dose From Radical Radiotherapy on All-Cause Mortality in Locally Advanced NSCLC.
J Thorac Oncol. 2023;18:14-16.
PubMed

BALASUBRAMANIAN A, John T
Safety of Dueling NSCLC With Dual Agent Immunotherapy.
J Thorac Oncol. 2023;18:10-13.
PubMed

DE CASTRO G JR, Rizvi NA, Schmid P, Syrigos K, et al
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
J Thorac Oncol. 2023;18:106-119.
PubMed Abstract available

DAGOGO-JACK I, Abbattista A, Murphy JF, Krulewicz S, et al
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
J Thorac Oncol. 2023;18:67-78.
PubMed Abstract available

YANG CY, Lin YT, Lin LJ, Chang YH, et al
Stage Shift Improves Lung Cancer Survival: Real-World Evidence.
J Thorac Oncol. 2023;18:47-56.
PubMed Abstract available

December 2022

OSAROGIAGBON RU, Van Schil P, Giroux DJ, Lim E, et al
The IASLC Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer.
J Thorac Oncol. 2022 Dec 23:S1556-0864(22)01985.
PubMed Abstract available

ERNST SM, Mankor J, van Riet J, von der Thusen JH, et al
Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.
J Thorac Oncol. 2022 Dec 14:S1556-0864(22)01961.
PubMed Abstract available

DEB D, Moore AC, Basu Roy U
In Response: Letter Received From Dr. Tadashi Nishimura Titled "What About Palliative and Supportive Care Landscapes?".
J Thorac Oncol. 2022;17:e95-e96.
PubMed

NISHIMURA T
What About Palliative and Supportive Care Landscapes?
J Thorac Oncol. 2022;17:e95.
PubMed

GROSSO F, Cerbone L, Pasello G
Pericardial Mesothelioma, a Disease for Brave Hearts.
J Thorac Oncol. 2022;17:1333-1334.
PubMed

BOGART JA
Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New Questions?
J Thorac Oncol. 2022;17:1330-1332.
PubMed

OFFIN M, De Silva DL, Sauter JL, Egger JV, et al
Multimodality Therapy in Patients With Primary Pericardial Mesothelioma.
J Thorac Oncol. 2022;17:1428-1432.
PubMed Abstract available

LIN EP, Hsu CY, Chiou JF, Berry L, et al
Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit.
J Thorac Oncol. 2022;17:1365-1374.
PubMed Abstract available

GARASSINO MC, Mazieres J, Reck M, Chouaid C, et al
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
J Thorac Oncol. 2022;17:1415-1427.
PubMed Abstract available

November 2022

FOUSEK K, Horn LA, Qin H, Dahut M, et al
An IL-15 superagonist enables anti-tumor efficacy of NK cells against all molecular variants of small cell lung cancer (SCLC).
J Thorac Oncol. 2022 Nov 18:S1556-0864(22)01910.
PubMed Abstract available

GARCIA-PARDO M, Chang A, Schmid S, Dong M, et al
Respiratory and cardiometabolic comorbidities and Stage I-III non-small cell lung cancer (NSCLC) survival: A pooled analysis from the International Lung Cancer Consortium (ILCCO).
J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01903.
PubMed Abstract available

GAO S, Jin L, Meadows HW, Shafman T, et al
Prediction of distant metastases after stereotactic body radiation therapy for early stage non-small cell lung cancer: development and external validation of a multi-institutional model.
J Thorac Oncol. 2022 Nov 14. pii: S1556-0864(22)01909.
PubMed Abstract available

MITSUDOMI T, Tan D, Yang JC, Ahn MJ, et al
Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.
J Thorac Oncol. 2022 Nov 12. pii: S1556-0864(22)01905.
PubMed Abstract available

October 2022

WANG Q, Gumus ZH, Colarossi C, Memeo L, et al
Small Cell Lung Cancer: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection.
J Thorac Oncol. 2022 Oct 12. pii: S1556-0864(22)01851.
PubMed Abstract available

PAIK PK, Fan PD, Qeriqi B, Namakydoust A, et al
Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228.
J Thorac Oncol. 2022 Oct 11. pii: S1556-0864(22)01825.
PubMed Abstract available

HOPKINS AM, Sorich MJ
Response to Mazzaschi and Buti.
J Thorac Oncol. 2022;17:e90.
PubMed

MAZZASCHI G, Buti S
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC?
J Thorac Oncol. 2022;17:e89-e90.
PubMed

SUMI T, Michimata H, Nagayama D, Koshino Y, et al
Tumor-Associated Raynaud's Phenomenon Exacerbated by Administration of Immune Checkpoint Inhibitors.
J Thorac Oncol. 2022;17:1233-1234.
PubMed

FENG J, Leighl NB
There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor.
J Thorac Oncol. 2022;17:1175-1177.
PubMed

DAGOGO-JACK I, Piotrowska Z
There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC.
J Thorac Oncol. 2022;17:1171-1174.
PubMed

CANGIR AK, Yumuk PF, Sak SD, Akyurek S, et al
Lung Cancer in Turkey.
J Thorac Oncol. 2022;17:1158-1170.
PubMed

MOUNTZIOS G, Aggarwal C
Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?
J Thorac Oncol. 2022;17:1155-1157.
PubMed

LAU SCM, Ou SI
And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC.
J Thorac Oncol. 2022;17:1144-1154.
PubMed

September 2022

SMELTZER MP, Liao W, Faris NR, Fehnel C, et al
Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening.
J Thorac Oncol. 2022 Sep 30. pii: S1556-0864(22)01820.
PubMed Abstract available

ZHOU C, Huang D, Fan Y, Yu X, et al
Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.
J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01803.
PubMed Abstract available

MINO-KENUDSON M, Schalper K, Cooper W, Dacic S, et al
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.
J Thorac Oncol. 2022 Sep 29. pii: S1556-0864(22)01695.
PubMed Abstract available

CRADDOCK M, Nestle U, Koenig J, Schimek-Jasch T, et al
Cardiac function modifies the impact of heart base dose on survival: A voxel-wise analysis of lung cancer patients from the PET-Plan trial.
J Thorac Oncol. 2022 Sep 18. pii: S1556-0864(22)01590.
PubMed

IGNATIUS OU SH, Nishio M, Ahn MJ, Mok T, et al
Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study.
J Thorac Oncol. 2022 Sep 9. pii: S1556-0864(22)01584.
PubMed Abstract available

IGNATIUS OU SH
In Response to Continuation of Lorlatinib Beyond Progressive Disease.
J Thorac Oncol. 2022;17:e86-e88.
PubMed

ZHAO B, Ma W
Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.
J Thorac Oncol. 2022;17:e85-e86.
PubMed

BOZINOVSKI S
Response to "Non-Tumor Cells in Tumor Specimens Impair the Accuracy of qPCR in the Detection of PD-L1 CNV and mRNA Expression".
J Thorac Oncol. 2022;17:e84-e85.
PubMed

ZHANG H, Chen Z, Li M, Sui Q, et al
Nontumor cells in Tumor Specimens Impair the Accuracy of Quantitative Polymerase Chain Reaction in the Detection of Programmed Death-Ligand 1 Copy Number Variant and mRNA Expression.
J Thorac Oncol. 2022;17:e83-e84.
PubMed

NICHOLSON AG, Scagliotti G, Tsao MS, Yatabe Y, et al
2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification.
J Thorac Oncol. 2022;17:e80-e83.
PubMed

JAVEY M, Yaung SJ
Incorporating Genetic Biomarkers in WHO Classification of Lung Cancer.
J Thorac Oncol. 2022;17:e79-e80.
PubMed

ZHAO B, Xing H, Ma W
Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations.
J Thorac Oncol. 2022;17:e76-e77.
PubMed

LEE J, Hong YS, Cho J, Lee J, et al
Comment on "Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?"
J Thorac Oncol. 2022;17:e74-e75.
PubMed

CHIAPPETTA M, Sassorossi C, Tabacco D, Lococo F, et al
Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?
J Thorac Oncol. 2022;17:e73-e74.
PubMed

LEE J, Ahn MJ
A Response to the Letter to the Editor: "Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer".
J Thorac Oncol. 2022;17:e72-e73.
PubMed

ZHAO B, Li H, Ma W
Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC.
J Thorac Oncol. 2022;17:e71-e72.
PubMed

NIYIBIZI BA, Muhizi E, Ndoli DA, Rukundo I, et al
Lung Cancer in Rwanda.
J Thorac Oncol. 2022;17:1074-1077.
PubMed

MATSUOKA R, Kawai H, Ito T, Matsubara D, et al
Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors.
J Thorac Oncol. 2022;17:1070-1073.
PubMed

GIRARD N
EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents.
J Thorac Oncol. 2022;17:1067-1069.
PubMed

WU TC, Lin CC
Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2022;17:1063-1066.
PubMed

KALCHIEM-DEKEL O, Falcon CJ, Bestvina CM, Liu D, et al
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
J Thorac Oncol. 2022;17:1130-1136.
PubMed Abstract available

BAINE MK, Febres-Aldana CA, Chang JC, Jungbluth AA, et al
POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
J Thorac Oncol. 2022;17:1109-1121.
PubMed Abstract available

August 2022

PAZ-ARES LG, Ciuleanu T, Pluzanski A, Lee JS, et al
Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01556.
PubMed Abstract available

HEIDEN BT, Eaton DB Jr, Chang SH, Yan Y, et al
Assessment of Updated Commission on Cancer Guidelines for Intraoperative Lymph Node Sampling in Early-stage Non-small Cell Lung Cancer.
J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01551.
PubMed Abstract available

VACHANI A, Carroll NM, Simoff MJ, Neslund-Dudas C, et al
Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose CT Screening.
J Thorac Oncol. 2022 Aug 29. pii: S1556-0864(22)01553.
PubMed Abstract available

REDIN E, Garrido-Martin EM, Valencia K, Redrado M, et al
YES1 is a druggable oncogenic target in Small Cell Lung Cancer.
J Thorac Oncol. 2022 Aug 18. pii: S1556-0864(22)01530.
PubMed Abstract available

SHI Y, Chen G, Wang X, Liu Y, et al
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
J Thorac Oncol. 2022 Aug 3. pii: S1556-0864(22)01496.
PubMed Abstract available

SMELTZER MP, Ray MA, Faris NR, Osarogiagbon RU, et al
Genie Out of the Bottle: Is There a Role for Gene-Gene Interactions in Early Detection of Lung Cancer?
J Thorac Oncol. 2022;17:946-948.
PubMed

ROE OD, Creaney J
Response to "Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma".
J Thorac Oncol. 2022;17:e69-e70.
PubMed

YANG H, Yao F, Peng RW
Revisiting "BAP1ness" in Malignant Pleural Mesothelioma.
J Thorac Oncol. 2022;17:e67-e69.
PubMed

YANG H, Gaudino G, Bardelli F, Carbone M, et al
Does the Amount of Asbestos Exposure Influence Prognosis?
J Thorac Oncol. 2022;17:949-952.
PubMed

SAVARI O, Chang JC, Bishop JA, Sakthivel MK, et al
First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
J Thorac Oncol. 2022;17:1050-1053.
PubMed Abstract available

BARBIERI PG, Consonni D, Somigliana A
Asbestos Lung Burden Does Not Predict Survival in Malignant Pleural Mesothelioma: A Necropsy-Based Study of 185 Cases.
J Thorac Oncol. 2022;17:1042-1049.
PubMed Abstract available

BUCKNELL NW, Belderbos J, Palma DA, Iyengar P, et al
Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective.
J Thorac Oncol. 2022;17:961-973.
PubMed Abstract available

LAAKSONEN S, Kettunen E, Sutinen E, Ilonen I, et al
Pulmonary Asbestos Fiber Burden Is Related to Patient Survival in Malignant Pleural Mesothelioma.
J Thorac Oncol. 2022;17:1032-1041.
PubMed Abstract available

July 2022

PASTORINO U, Ladisa V, Trussardo S, Sabia F, et al
Cytisine therapy improved smoking cessation in the randomized SMILE lung cancer screening trial.
J Thorac Oncol. 2022 Jul 21. pii: S1556-0864(22)00346.
PubMed Abstract available

XIONG A, Ren S, Liu H, Miao L, et al
Efficacy and safety of SH-1028 in patients with EGFR T790M positive non-small-cell lung cancer: a multicenter, single-arm, open-label, phase 2 trial.
J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00327.
PubMed Abstract available

VOTH PARK J, Chandra R, Cai L, Ganguly D, et al
Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the non-small cell lung cancer tumor microenvironment.
J Thorac Oncol. 2022 Jul 4. pii: S1556-0864(22)00315.
PubMed Abstract available

CAVIC M, Kovacevic T, Zaric B, Stojiljkovic D, et al
Lung Cancer in Serbia.
J Thorac Oncol. 2022;17:867-872.
PubMed

NIHO S
Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy.
J Thorac Oncol. 2022;17:865-866.
PubMed

GHAFOOR A, Hassan R
Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy.
J Thorac Oncol. 2022;17:862-864.
PubMed

LOUW A, Panou V, Szejniuk WM, Meristoudis C, et al
BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
J Thorac Oncol. 2022;17:921-930.
PubMed Abstract available

CARBONE M, Pass HI, Ak G, Alexander HR Jr, et al
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.
J Thorac Oncol. 2022;17:873-889.
PubMed Abstract available

HIGASHIYAMA RI, Yoshida T, Yagishita S, Ohuchi M, et al
Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer.
J Thorac Oncol. 2022 Jul 1. pii: S1556-0864(22)00314.
PubMed Abstract available

June 2022

FERNANDEZ AI, Gavrielatou N, McCann L, Shafi S, et al
PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer.
J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00311.
PubMed Abstract available

RECK M, Mok TSK, Mansfield A, De Boer R, et al
Brief Report: Exploratory analysis of maintenance therapy in patients with extensive-stage small cell lung cancer treated first-line with atezolizumab plus carboplatin and etoposide.
J Thorac Oncol. 2022 Jun 25. pii: S1556-0864(22)00300.
PubMed Abstract available

HIBINO M, Uryu K, Takeda T, Kunimatsu Y, et al
Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
J Thorac Oncol. 2022 Jun 22. pii: S1556-0864(22)00295.
PubMed Abstract available

LU S, Zhang Y, Zhang G, Zhou J, et al
Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study.
J Thorac Oncol. 2022 Jun 17. pii: S1556-0864(22)00297.
PubMed Abstract available

CARDONA AF, Mejia SA, Viola L, Chamorro DF, et al
Lung Cancer in Colombia.
J Thorac Oncol. 2022 Jun 15. pii: S1556-0864(22)00217.
PubMed

NGUYEN EM, Taniguchi H, Chan JM, Zhan YA, et al
Targeting LSD1 rescues MHC class I antigen presentation and overcomes PD-L1 blockade resistance in small cell lung cancer.
J Thorac Oncol. 2022 Jun 9. pii: S1556-0864(22)00273.
PubMed Abstract available

RICCIUTI B, Awad MM
Reply to Kus and Aktas.
J Thorac Oncol. 2022;17:e64-e65.
PubMed

KUS T, Aktas G
Letter to the Editor Concerning Diminished Efficacy of Programmed Death-(Ligand) 1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
J Thorac Oncol. 2022;17:e63-e64.
PubMed

MOK T
In Response to Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
J Thorac Oncol. 2022;17:e62-e63.
PubMed

LI M
Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX.
J Thorac Oncol. 2022;17:e61-e62.
PubMed

CANDAL-PEDREIRA C, Ruano-Ravina A, Provencio M, Fernandez-Villar A, et al
Does the Age of Inclusion in Lung Cancer Screening Studies Overestimate the Benefits?
J Thorac Oncol. 2022;17:e59-e61.
PubMed

SALEH MM, Scheffler M, Merkelbach-Bruse S, Wolf J, et al
Reply to: "Survival Analysis of TP53 Co-Mutations Should be Interpreted More Cautiously".
J Thorac Oncol. 2022;17:e57-e59.
PubMed

BRADA M, Forbes H, Ashley S, Fenwick J, et al
Robust Comprehensive Dataset Provides Pause for Thought.
J Thorac Oncol. 2022;17:e56-e57.
PubMed

SALEM A, Franks K, Greystoke A, Hanna GG, et al
Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC.
J Thorac Oncol. 2022;17:e55-e56.
PubMed

WRIGHT GM, Goodwin D
Response to Letter: Beyond "Personalized" to "Tumoralized" Therapy.
J Thorac Oncol. 2022;17:e54.
PubMed

GOTO T
Beyond Personalized to "Tumoralized" Therapy.
J Thorac Oncol. 2022;17:e53-e54.
PubMed

FROST N, Griesinger F, Hoffmann H, Langer F, et al
Lung Cancer in Germany.
J Thorac Oncol. 2022;17:742-750.
PubMed

CORTELLINI A, Facchinetti F, Derosa L, Pinato DJ, et al
Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters.
J Thorac Oncol. 2022;17:739-741.
PubMed

ATAY SM, Kim AW
Possibly Two Birds or One Squirrel.
J Thorac Oncol. 2022;17:737-738.
PubMed

RITTBERG R, Abraham N, Laskin J, Ho C, et al
Hyper-Sensitive? Targeted Therapy With a Primed Immune System.
J Thorac Oncol. 2022;17:734-736.
PubMed

VOKES NI, Chambers E, Nguyen T, Coolidge A, et al
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
J Thorac Oncol. 2022;17:779-792.
PubMed Abstract available

RUFFINI E, Rami-Porta R, Huang J, Ahmad U, et al
The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Unresolved Issues to be Addressed for the Next Ninth Edition of the TNM Classification of Malignant Tumors.
J Thorac Oncol. 2022;17:838-851.
PubMed Abstract available

SHIN DW, Cho JH, Ha J, Jung KW, et al
Trends in Incidence and Survival of Patients With Thymic Epithelial Tumor in a High-Incidence Asian Country: Analysis of the Korean Central Cancer Registry 1999 to 2017.
J Thorac Oncol. 2022;17:827-837.
PubMed Abstract available

SHI Y, Li B, Wu L, Pan Y, et al
Efficacy and safety of Limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer: a multicenter, single-arm, phase 2b study.
J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00267.
PubMed Abstract available

PICCIRILLO MC, Bonanno L, Garassino MC, Esposito G, et al
Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial.
J Thorac Oncol. 2022 Jun 1. pii: S1556-0864(22)00268.
PubMed Abstract available

May 2022

KENMOTSU H, Wakuda K, Mori K, Kato T, et al
Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations; WJOG9717L study.
J Thorac Oncol. 2022 May 27. pii: S1556-0864(22)00265.
PubMed Abstract available

ZHANG F, Guo W, Zhou B, Wang S, et al
Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
J Thorac Oncol. 2022 May 9. pii: S1556-0864(22)00216.
PubMed Abstract available

SHEIKH HS, Munawar K, Sheikh F, Qamar MFU, et al
Lung Cancer in Pakistan.
J Thorac Oncol. 2022;17:602-607.
PubMed

POLERI C
Sex-Based Differences in Lung Cancer: Does It Matter?
J Thorac Oncol. 2022;17:599-601.
PubMed

EVANS WK, Warren GW, Dresler C
Ignoring the Obvious: Smoking Cessation Improves Survival.
J Thorac Oncol. 2022;17:596-598.
PubMed

WOODARD GA, Cho C, Chen L
Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?
J Thorac Oncol. 2022;17:592-595.
PubMed

ZHANG C, Wu YL, Zhong WZ
New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019.
J Thorac Oncol. 2022;17:588-591.
PubMed

FUJIKAWA R, Muraoka Y, Kashima J, Yoshida Y, et al
Clinicopathologic and Genotypic Features of Lung Adenocarcinoma Characterized by the International Association for the Study of Lung Cancer Grading System.
J Thorac Oncol. 2022;17:700-707.
PubMed Abstract available

RODEN AC, Ahmad U, Cardillo G, Girard N, et al
Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group.
J Thorac Oncol. 2022;17:637-650.
PubMed Abstract available

AUJLA S, Aloe C, Vannitamby A, Hendry S, et al
Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype.
J Thorac Oncol. 2022;17:675-687.
PubMed Abstract available

SAUTER JL, Dacic S, Galateau-Salle F, Attanoos RL, et al
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
J Thorac Oncol. 2022;17:608-622.
PubMed Abstract available

April 2022

ZHANG R, Shen S, Wei Y, Zhu Y, et al
A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians.
J Thorac Oncol. 2022 Apr 29. pii: S1556-0864(22)00215.
PubMed Abstract available

MOUTAFI M, Martinez-Morilla S, Divakar P, Vathiotis I, et al
Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling.
J Thorac Oncol. 2022 Apr 28. pii: S1556-0864(22)00212.
PubMed Abstract available

DEB D, Moore AC, Roy UB
2021 global lung cancer therapy landscape.
J Thorac Oncol. 2022 Apr 27. pii: S1556-0864(22)00211.
PubMed Abstract available

LEE J, Hong YS, Cho J, Lee J, et al
Reclassifying the IASLC R Classification According to the Extent of Nodal Dissection for Non-Small Cell Lung Cancer: One Size Does Not Fit All.
J Thorac Oncol. 2022 Apr 21. pii: S1556-0864(22)00195.
PubMed Abstract available

LEE J, Koh J, Kim HK, Hong S, et al
Bevacizumab plus atezolizumab following progression on atezolizumab monotherapy in pretreated non-small cell lung cancer patients: An open-label, two-stage, phase II trial.
J Thorac Oncol. 2022 Apr 12. pii: S1556-0864(22)00193.
PubMed Abstract available

ELHASSAN MMA, Mohamedani AA, Mohamed SAH, Hamdoun AOA, et al
Lung Cancer in Sudan.
J Thorac Oncol. 2022;17:489-498.
PubMed

REGUART N, Reyes R
Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors.
J Thorac Oncol. 2022;17:477-480.
PubMed

YANG SR, Rekhtman N
Molecular Testing Identifies Ultra-Late Recurrences in Lung Carcinomas: Implications for Clinical Management.
J Thorac Oncol. 2022;17:e50-e51.
PubMed

GOTO T
Genomically Metastatic, but Surgically Curable?
J Thorac Oncol. 2022;17:e49-e50.
PubMed

LIN Y, Fu M, Inoue K, Jeon CY, et al
Response to Letter to the Editor.
J Thorac Oncol. 2022;17:e47-e48.
PubMed

TANG W, Lu L, Gu JW, Chen HL, et al
Some Thoughts Concerning the Patient Adherence to Lung Computed Tomography Screening Reporting and Data System-Recommended Screening Intervals.
J Thorac Oncol. 2022;17:e45-e46.
PubMed

ROSNER S, Forde PM
Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
J Thorac Oncol. 2022;17:503-509.
PubMed

HENDRIKS LEL, Remon J, Reck M
Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC.
J Thorac Oncol. 2022;17:499-502.
PubMed

PUTORA PM, De Ruysscher DK
Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC?
J Thorac Oncol. 2022;17:487-488.
PubMed

WANG F, Zhou Q
The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC.
J Thorac Oncol. 2022;17:481-486.
PubMed

OU SI, Solomon BJ, Shaw AT, Gadgeel SM, et al
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
J Thorac Oncol. 2022;17:568-577.
PubMed Abstract available

FOLCH EE, Bowling MR, Pritchett MA, Murgu SD, et al
NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States.
J Thorac Oncol. 2022;17:519-531.
PubMed Abstract available

MALESZEWSKI JJ, Basso C, Bois MC, Glass C, et al
The 2021 WHO Classification of Tumors of the Heart.
J Thorac Oncol. 2022;17:510-518.
PubMed

March 2022

SCALERA S, Mazzotta M, Cortile C, Krasniqi E, et al
Concise Review: Gene of The Month KEAP1-mutant non-small cell lung cancer: the catastrophic failure of a cell-protecting hub.
J Thorac Oncol. 2022 Mar 26. pii: S1556-0864(22)00166.
PubMed Abstract available

JAIN D, Nambirajan A, Chen G, Geisinger K, et al
Non-small cell lung carcinoma subtyping in conventional cytology: Results of the IASLC Cytology Working Group survey to determine specific cytomorphological criteria for adenocarcinoma and squamous cell carcinoma.
J Thorac Oncol. 2022 Mar 21. pii: S1556-0864(22)00145.
PubMed Abstract available

LU S, Zhou Q, Liu X, Du Y, et al
Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.
J Thorac Oncol. 2022 Mar 17. pii: S1556-0864(22)00147.
PubMed Abstract available

DETTERBECK FC, Nishimura KK, Cilento VJ, Giuliani M, et al
The IASLC Lung Cancer Staging Project: Methods and Guiding Principles for the Development of the 9(th) Edition TNM Classification.
J Thorac Oncol. 2022 Mar 9. pii: S1556-0864(22)00107.
PubMed Abstract available

SCALERA S, Mazzotta M, Cappuzzo F, Ciliberto G, et al
KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously".
J Thorac Oncol. 2022;17:e40-e41.
PubMed

HORINOUCHI H, Kusumoto M, Yatabe Y, Aokage K, et al
Lung Cancer in Japan.
J Thorac Oncol. 2022;17:353-361.
PubMed

TEN HAAF K
Informing Patient Surveillance for the Growing Number of Survivors of Lung Cancer.
J Thorac Oncol. 2022;17:345-347.
PubMed

PELOSI G
Labeling Lung Neuroendocrine Neoplasms for Ki-67 Antigen to Score a Bull's-Eye, Not Shoot in the Dark.
J Thorac Oncol. 2022;17:e41-e44.
PubMed

LE X, Heymach J
In Response.
J Thorac Oncol. 2022;17:e39.
PubMed

FERRARA R, Milani M, Garassino MC, Colombo MP, et al
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction?
J Thorac Oncol. 2022;17:e35-e38.
PubMed

FAN C, Zhao Q, Teng C, Jiang Z, et al
Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?"
J Thorac Oncol. 2022;17:e33-e34.
PubMed

PAN Z
Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases From NSCLC.
J Thorac Oncol. 2022;17:e31-e32.
PubMed

ZHANG Y, Deng C, Zheng Q, Li Y, et al
The Grading System of Lung Adenocarcinoma: Ever-Evolving Concepts.
J Thorac Oncol. 2022;17:e30.
PubMed

LI S, Deng J, She Y, Hou L, et al
Clinical Thoughts on the Predictive Value of the Newly Proposed Grading System of Invasive Pulmonary Adenocarcinoma.
J Thorac Oncol. 2022;17:e28-e29.
PubMed

LIN Y, Fu M, Inoue K, Jeon CY, et al
Response to Letter to the Editor.
J Thorac Oncol. 2022;17:e27-e28.
PubMed

RAJAGOPAL MS, Senthilnathan R, Km G, Ram M R, et al
Conceptual and Statistical Interpretation of a Systematic Review and Meta-Analysis on Patient Adherence to Lung-RADS-Recommended Screening Intervals in the United States.
J Thorac Oncol. 2022;17:e25-e27.
PubMed

DZIADZIUSZKO R
STK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues.
J Thorac Oncol. 2022;17:351-352.
PubMed

CAMIDGE DR
The Magic of ADAURA?
J Thorac Oncol. 2022;17:348-350.
PubMed

LU S, Li Z
Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.
J Thorac Oncol. 2022;17:341-344.
PubMed

TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
Reprint of "Introduction to 2021 WHO Classification of Thoracic Tumors".
J Thorac Oncol. 2022;17:337-340.
PubMed

NICHOLSON AG, Tsao MS, Beasley MB, Borczuk AC, et al
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.
J Thorac Oncol. 2022;17:362-387.
PubMed Abstract available

LU S, Wang Q, Zhang G, Dong X, et al
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
J Thorac Oncol. 2022;17:411-422.
PubMed Abstract available

KOSARI F, Disselhorst M, Yin J, Peikert T, et al
Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.
J Thorac Oncol. 2022;17:446-454.
PubMed Abstract available

RICCIUTI B, Arbour KC, Lin JJ, Vajdi A, et al
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
J Thorac Oncol. 2022;17:399-410.
PubMed Abstract available

WU YL, John T, Grohe C, Majem M, et al
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
J Thorac Oncol. 2022;17:423-433.
PubMed Abstract available

OFFIN M, Yang SR, Egger J, Jayakumaran G, et al
Molecular Characterization of Peritoneal Mesotheliomas.
J Thorac Oncol. 2022;17:455-460.
PubMed Abstract available

HU ZI, Miettinen M, Quezado M, Lebensohn AP, et al
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
J Thorac Oncol. 2022;17:461-466.
PubMed Abstract available

February 2022

MCCOACH CE, Rolfo C, Drilon A, Lacouture M, et al
Hypersensitivity Reactions to Selpercatinib Treatment with or Without Prior Immune Checkpoint Inhibitor Therapy in Patients with Non-Small-Cell Lung Cancer in LIBRETTO-001.
J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00094.
PubMed Abstract available

HOPKINS AM, Badaoui S, Kichenadasse G, Karapetis CS, et al
Efficacy of atezolizumab in patients with advanced non-small cell lung cancer receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomised control trials.: Proton pump inhibitors, antibiotics, and immunothera
J Thorac Oncol. 2022 Feb 17. pii: S1556-0864(22)00093.
PubMed Abstract available

SMELTZER MP, Scagliotti GV, Wakelee HA, Mitsudomi T, et al
International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials.
J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00086.
PubMed Abstract available

AHN MJ, Cho BC, Ou X, Walding A, et al
Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial.
J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00081.
PubMed Abstract available

SHI Y, Zhao Y, Yang S, Zhou J, et al
Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.
J Thorac Oncol. 2022 Feb 15. pii: S1556-0864(22)00084.
PubMed Abstract available

YU XQ, Yap ML, Cheng ES, Ngo PJ, et al
Evaluating prognostic factors for sex differences in lung cancer survival: findings from a large Australian cohort.
J Thorac Oncol. 2022 Feb 3. pii: S1556-0864(22)00085.
PubMed

KERPEL-FRONIUS A, Tammemagi MC, Cavic M, Huber RM, et al
Lung Cancer Screening in Persons Who Never Smoked Has to be Evaluated-A Response to Letter to the Editor.
J Thorac Oncol. 2022;17:e20-e21.
PubMed

FU F, Zhang Y, He N, Chen H, et al
Emerging High-Risk Population of Lung Cancer: To Reveal the Unrevealed.
J Thorac Oncol. 2022;17:e18-e20.
PubMed

NAVANI N, Baldwin DR, Edwards JG, Evison M, et al
Lung Cancer in the United Kingdom.
J Thorac Oncol. 2022;17:186-193.
PubMed

DERKS JL, Dingemans AC, Speel EM
Molecular Knowledge and Clinical Relevance - Stepping Stones in Improving Classification of Lung Neuroendocrine Neoplasms.
J Thorac Oncol. 2022;17:e8-e10.
PubMed

PELOSI G
The Natural History in Lung Neuroendocrine Neoplasms: The Stone Guest Who Matters.
J Thorac Oncol. 2022;17:e5-e8.
PubMed

MOONEN L, Derks JL, Dingemans AC, Speel EJM, et al
Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull's Eye.
J Thorac Oncol. 2022;17:e21-e23.
PubMed

LIN A, Luo P, Zhang J
Survival Analysis of TP53 Comutations Should Be Interpreted More Cautiously.
J Thorac Oncol. 2022;17:e14-e18.
PubMed

THOMAS NJ, Myall NJ, Sun F, Patil T, et al
In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
J Thorac Oncol. 2022;17:e12-e14.
PubMed

NARDONE V, Correale P, Mutti L, Desideri I, et al
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
J Thorac Oncol. 2022;17:e10-e12.
PubMed

FAIVRE-FINN C, Edwards JG, Hatton M
Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC.
J Thorac Oncol. 2022;17:197-199.
PubMed

LIU J, Ladbury C, Kim J, Raz D, et al
Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.
J Thorac Oncol. 2022;17:194-196.
PubMed

NAGASAKA M, Ou SI
Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy.
J Thorac Oncol. 2022;17:182-185.
PubMed

MUTHUSAMY B, Pennell N
Chemoimmunotherapy for EGFR-Mutant NSCLC: Still No Clear Answer.
J Thorac Oncol. 2022;17:179-181.
PubMed

LIN YT, Shih JY
Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors in NSCLC: Two Heads Are Better Than One.
J Thorac Oncol. 2022;17:176-178.
PubMed

LASVERGNAS J, Playe M, Saint-Val L, Brillet PY, et al
Pitfalls in Cancer Evaluation in Case of Chronic Superior Vena Cava Obstruction: Vertebral Enhancement and Hot Quadrate Sign in the Liver.
J Thorac Oncol. 2022;17:324-326.
PubMed

MARX A, Chan JKC, Chalabreysse L, Dacic S, et al
The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
J Thorac Oncol. 2022;17:200-213.
PubMed Abstract available

NOGAMI N, Barlesi F, Socinski MA, Reck M, et al
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
J Thorac Oncol. 2022;17:309-323.
PubMed Abstract available

January 2022

BRADA M, Forbes H, Ashley S, Fenwick J, et al
Improving outcomes in non-small cell lung cancer; optimum dose fractionation in radical radiotherapy matters.
J Thorac Oncol. 2022 Jan 26. pii: S1556-0864(22)00051.
PubMed Abstract available

WHISENANT JG, Baena J, Cortellini A, Huang LC, et al
A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry.
J Thorac Oncol. 2022 Jan 24. pii: S1556-0864(22)00033.
PubMed Abstract available

SHILPAKAR R, Paudel BD, Sharma R, Silwal SR, et al
Lung Cancer in Nepal.
J Thorac Oncol. 2022;17:22-29.
PubMed

MASAGO K, Fujita S
Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment.
J Thorac Oncol. 2022;17:16-18.
PubMed

SALLOUM RG, Braithwaite D
Expansion of Guideline-Recommended Lung Cancer Screening Eligibility: Implications for Health Equity of Joint Screening and Cessation Interventions.
J Thorac Oncol. 2022;17:13-15.
PubMed

TSAO MS, Nicholson AG, Maleszewski JJ, Marx A, et al
Introduction to 2021 WHO Classification of Thoracic Tumors.
J Thorac Oncol. 2022;17:e1-e4.
PubMed

FENNELL DA, Dulloo S
Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
J Thorac Oncol. 2022;17:34-37.
PubMed

BAAS P
Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.
J Thorac Oncol. 2022;17:30-33.
PubMed

JOUBERT P, Travis WD
Prognostic Impact of Ground-Glass Opacity/Lepidic Component in Pulmonary Adenocarcinoma: A Hazy Staging Dilemma.
J Thorac Oncol. 2022;17:19-21.
PubMed

YAMAMOTO H, Togashi Y
Programmed Death-Ligand 1-Rich Premetastatic Niche in Adjuvant Chemotherapy.
J Thorac Oncol. 2022;17:10-12.
PubMed

GROSS DJ, Chintala NK, Vaghjiani RG, Grosser R, et al
Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.
J Thorac Oncol. 2022;17:89-102.
PubMed Abstract available

OKUBO Y, Kashima J, Teishikata T, Muraoka Y, et al
Prognostic Impact of the Histologic Lepidic Component in Pathologic Stage IA Adenocarcinoma.
J Thorac Oncol. 2022;17:67-75.
PubMed Abstract available

LIN Y, Fu M, Ding R, Inoue K, et al
Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis.
J Thorac Oncol. 2022;17:38-55.
PubMed Abstract available

December 2021

CHO BC, Han JY, Kim SW, Lee KH, et al
A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2021 Dec 24. pii: S1556-0864(21)03403.
PubMed Abstract available

CAINI S, Del Riccio M, Vettori V, Scotti V, et al
Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis.
J Thorac Oncol. 2021 Dec 17. pii: S1556-0864(21)03404.
PubMed Abstract available

REN S, Chen J, Xu X, Jiang T, et al
Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.
J Thorac Oncol. 2021 Dec 16. pii: S1556-0864(21)03392.
PubMed Abstract available

EBERL M, Tanaka LF, Kraywinkel K, Klug SJ, et al
Incidence of smoking-related second primary cancers after lung cancer in Germany: an analysis of nationwide cancer registry data.
J Thorac Oncol. 2021 Dec 10. pii: S1556-0864(21)03390.
PubMed Abstract available

HUBER RM, Cavic M, Kerpel-Fronius A, Viola L, et al
Lung Cancer Screening Considerations During Respiratory Infection Outbreaks, Epidemics or Pandemics: An IASLC Early Detection and Screening Committee Report.
J Thorac Oncol. 2021 Dec 2. pii: S1556-0864(21)03326.
PubMed Abstract available

PARK S, Choi CM, Hwang SS, Choi YL, et al
Lung Cancer in Korea.
J Thorac Oncol. 2021;16:1988-1993.
PubMed

BIAN Y, Liang J, Shan G, Zhan C, et al
Combining Clinical and Molecular Characteristics to Precisely Predict the Prognosis of Malignant Pleural Mesothelioma.
J Thorac Oncol. 2021;16:e99-e100.
PubMed

KUMAR A, Kumar S, Gilja S, Potter A, et al
Encouraging Guideline-Concordant Treatment for T3 NSCLC.
J Thorac Oncol. 2021;16:e98-e99.
PubMed

LI M, Liang J, Bi G, Zhan C, et al
Could T3Satell Tumors Be Considered Reclassified as T2b?
J Thorac Oncol. 2021;16:e97-e98.
PubMed

MORGENSZTERN D, Govindan R
Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
J Thorac Oncol. 2021;16:1999-2001.
PubMed

AREDO JV, Hellyer JA, Neal JW, Wakelee HA, et al
Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:1994-1998.
PubMed

BELDA-SANCHIS J, Trujillo-Reyes JC, Martinez-Tellez E, Cladellas-Gutierrez E, et al
Brain Metastasis From Thymic Epithelial Tumors: Strengthening the Evidence, a Call for Action.
J Thorac Oncol. 2021;16:1984-1987.
PubMed

PELOSI G
KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
J Thorac Oncol. 2021;16:1979-1983.
PubMed

BUGLIONI S, Marino M
Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community.
J Thorac Oncol. 2021;16:1976-1978.
PubMed

BENITEZ JC, Boucher ME, Dansin E, Kerjouan M, et al
Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight From RYTHMIC.
J Thorac Oncol. 2021;16:2144-2149.
PubMed Abstract available

SCALERA S, Mazzotta M, Corleone G, Sperati F, et al
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
J Thorac Oncol. 2021;16:2065-2077.
PubMed Abstract available

TEISHIKATA T, Shiraishi K, Shinno Y, Kobayashi Y, et al
An Alert to Possible False Positives With a Commercial Assay for MET Exon 14 Skipping.
J Thorac Oncol. 2021;16:2133-2138.
PubMed Abstract available

YANG Y, Sun J, Wang Z, Fang J, et al
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
J Thorac Oncol. 2021;16:2109-2120.
PubMed Abstract available

November 2021

LEIGHL NB, Laurie SA, Goss GD, Hughes BGM, et al
CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.
J Thorac Oncol. 2021 Nov 17. pii: S1556-0864(21)03322.
PubMed Abstract available

ROLFO C, Meshulami N, Russo A, Krammer F, et al
Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation.
J Thorac Oncol. 2021 Nov 10. pii: S1556-0864(21)03309.
PubMed Abstract available

GOUNANT V, Ferre VM, Soussi G, Charpentier C, et al
Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses.
J Thorac Oncol. 2021 Nov 2. pii: S1556-0864(21)03286.
PubMed Abstract available

STOCK-MARTINEAU S, Shepherd FA
EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:1793-1797.
PubMed

MOORE S, Wheatley-Price P
EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:1788-1792.
PubMed

YANG C, Li Y, Xiao SY
Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?
J Thorac Oncol. 2021;16:1785-1787.
PubMed

LOPEZ-CASTRO R, Recondo G, Gorria T, Mezquita L, et al
A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma.
J Thorac Oncol. 2021;16:1782-1784.
PubMed

ZHU VW, Ou SI
Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
J Thorac Oncol. 2021;16:1778-1781.
PubMed

ADJEI AA
Tackling the High Cost of Oncology Drugs.
J Thorac Oncol. 2021;16:1774-1777.
PubMed

DE BAERE T, Woodrum D, Tselikas L, Abtin F, et al
The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up.
J Thorac Oncol. 2021;16:1840-1849.
PubMed Abstract available

MIKUBO M, Inoue Y, Liu G, Tsao MS, et al
Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
J Thorac Oncol. 2021;16:1798-1809.
PubMed Abstract available

VAN DEN BROEK MFM, Levy S, Buikhuisen WA, Dijke K, et al
Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.
J Thorac Oncol. 2021;16:1810-1820.
PubMed Abstract available

CHIAPPETTA M, Lococo F, Zanfrini E, Moroni R, et al
The International Thymic Malignancy Interest Group Classification of Thymoma Recurrence: Survival Analysis and Perspectives.
J Thorac Oncol. 2021;16:1936-1945.
PubMed Abstract available

SAALFELD FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, et al
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
J Thorac Oncol. 2021;16:1952-1958.
PubMed Abstract available

YEAP BY, De Rienzo A, Gill RR, Oster ME, et al
Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma.
J Thorac Oncol. 2021;16:1925-1935.
PubMed Abstract available

October 2021

PAZ-ARES LG, Ramalingam SS, Ciuleanu TE, Lee JS, et al
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03207.
PubMed Abstract available

MEZA R, Cao P, Jeon J, Taylor KL, et al
Brief Report: Impact of joint lung cancer screening and cessation interventions under the new USPSTF recommendations.
J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03208.
PubMed Abstract available

ROBBINS HA, Cheung LC, Chaturvedi AK, Baldwin DR, et al
Management of lung cancer screening results based on individual prediction of current and future lung cancer risk.
J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03244.
PubMed Abstract available

HUO KG, Notsuda H, Fang Z, Liu NF, et al
Lung cancer driven by BRAF(G469V) mutation is targetable by EGFR kinase inhibitors.
J Thorac Oncol. 2021 Oct 11. pii: S1556-0864(21)03205.
PubMed Abstract available

SONG Z, Lian S, Mak S, Chow MZ, et al
Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer.
J Thorac Oncol. 2021 Oct 6. pii: S1556-0864(21)03219.
PubMed Abstract available

DZIADZIUSZKO R, Didkowska J, Jassem J
Authors' Reply to Role of Primary Prevention in Lung Cancer Control in Poland.
J Thorac Oncol. 2021;16:e94-e95.
PubMed

ZATONSKI WA, Janik-Koncewicz K, Zatonski M
Role of Primary Prevention in Lung Cancer Control in Poland.
J Thorac Oncol. 2021;16:e93-e94.
PubMed

OCAK S, Tournoy K, Berghmans T, Demedts I, et al
Lung Cancer in Belgium.
J Thorac Oncol. 2021;16:1610-1621.
PubMed

TSIM S, Alexander L, Kelly C, Shaw A, et al
Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
J Thorac Oncol. 2021;16:1705-1717.
PubMed Abstract available

DERKS JL, Rijnsburger N, Hermans BCM, Moonen L, et al
Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice.
J Thorac Oncol. 2021;16:1632-1646.
PubMed Abstract available

LUO J, Beattie JA, Fuentes P, Rizvi H, et al
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
J Thorac Oncol. 2021;16:1759-1764.
PubMed Abstract available

DENG C, Zheng Q, Zhang Y, Jin Y, et al
Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations.
J Thorac Oncol. 2021;16:1684-1693.
PubMed Abstract available

MYRAND SP
A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET.
J Thorac Oncol. 2021;16:e95.
PubMed

SUTEJA L, Yeong J, Tan AC, Toy W, et al
Improving Precision and Implementation of Immuno-Oncology Biomarkers.
J Thorac Oncol. 2021;16:e91-e93.
PubMed

YANG H, Hall SRR, Yao F
Improving Prediction Marker Models With the Ratio of CD39+CD8+ to Total CD8+ T cells: How Good Is Good Enough?
J Thorac Oncol. 2021;16:e88-e91.
PubMed

ZHAO H, Li J, Zhang Z, Zhang L, et al
Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials".
J Thorac Oncol. 2021;16:e87-e88.
PubMed

DAO QL, Phung Q, Liu MA
Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials.
J Thorac Oncol. 2021;16:e86-e87.
PubMed

FAN C, Zhao Q, Jiang Z, Xin T, et al
Response to Letter to the Editor Titled "Intrathecal Pemetrexed: Another Potential Treatment Modality for TKI-Failed Leptomeningeal Metastases?".
J Thorac Oncol. 2021;16:e85.
PubMed

ZHENG MM, Li YS, Sun H, Chen HJ, et al
Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases?
J Thorac Oncol. 2021;16:e82-e84.
PubMed

LINDBERG K, Lax I, Karlsson K, Lewensohn R, et al
In Response to Rosenberg et al. "The Nordic-HILUS Trial: Ultracentral Lung SABR and a Narrow Therapeutic Window".
J Thorac Oncol. 2021;16:e81-e82.
PubMed

ROSENBERG SA, Mak R, Kotecha R, Loo BW Jr, et al
The Nordic-HILUS Trial: Ultracentral Lung Stereotactic Ablative Radiotherapy and a Narrow Therapeutic Window.
J Thorac Oncol. 2021;16:e79-e80.
PubMed

STIRLING RG
Posttreatment Surveillance Challenges in the Era of Precision Medicine.
J Thorac Oncol. 2021;16:e77-e78.
PubMed

ARIK Z, Erman M
Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?
J Thorac Oncol. 2021;16:e77.
PubMed

ZHANG JT, Wu YL
Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2021;16:1627-1631.
PubMed

ZHOU F, Zhou C
Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors.
J Thorac Oncol. 2021;16:1622-1626.
PubMed

MESCI A, Tsakiridis T, Swaminath A
Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
J Thorac Oncol. 2021;16:1607-1609.
PubMed

BOTTICELLA A, Levy A, Le Pechoux C
Stage III NSCLC in Low- and Middle-Income Countries: Where Are We in 2021?
J Thorac Oncol. 2021;16:1605-1606.
PubMed

NICHOLSON AG, Moreira AL, Mino-Kenudson M, Popat S, et al
Grading in Lung Adenocarcinoma: Another New Normal.
J Thorac Oncol. 2021;16:1601-1604.
PubMed

ROKUTAN-KURATA M, Yoshizawa A, Ueno K, Nakajima N, et al
Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma.
J Thorac Oncol. 2021;16:1753-1758.
PubMed Abstract available

September 2021

SALEH MM, Scheffler M, Merkelbach-Bruse S, Scheel AH, et al
Comprehensive Analysis of TP53 and KEAP1 Mutations and their Impact on Survival in Localized and Advanced Stage Non-Small Cell Lung Cancer.
J Thorac Oncol. 2021 Sep 30. pii: S1556-0864(21)03187.
PubMed Abstract available

QU S, Fetsch P, Thomas A, Pommier Y, et al
Molecular Subtypes of Primary Small Cell Lung Cancer Tumors and Their Associations with Neuroendocrine and Therapeutic Markers.
J Thorac Oncol. 2021 Sep 14. pii: S1556-0864(21)03186.
PubMed Abstract available

NISHINO M, Hatabu H, Ricciuti B, Vaz V, et al
Brief Report Axillary lymphadenopathy after COVID-19 vaccinations in patients with thoracic malignancy: Incidence, predisposing factors, and imaging characteristics.
J Thorac Oncol. 2021 Sep 7. pii: S1556-0864(21)03184.
PubMed Abstract available

BESTVINA CM, Pointer KB, Karrison T, Al-Hallaq H, et al
A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study).
J Thorac Oncol. 2021 Sep 6. pii: S1556-0864(21)02441.
PubMed Abstract available

TRAN HTT, Nguyen S, Nguyen KK, Pham DX, et al
Lung Cancer in Vietnam.
J Thorac Oncol. 2021;16:1443-1448.
PubMed

SINGH AK, Sands JM
Yet Another Reminder of the Value of Lung Cancer Screening.
J Thorac Oncol. 2021;16:1437-1439.
PubMed

ZHAO H, Zhang Z, Zhang L
Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation.
J Thorac Oncol. 2021;16:e72-e76.
PubMed

YAMAOKA T, Kim YH, Iwatsubo S, Nishimura Y, et al
The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR Mutation.
J Thorac Oncol. 2021;16:e71-e72.
PubMed

BORZI C, Caiola E, Ganzinelli M, Centonze G, et al
miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC.
J Thorac Oncol. 2021;16:e68-e70.
PubMed

BI G, Liang J, Shan G, Zhan C, et al
Some Thoughts Concerning the Mutational Background of Cell Lines and Heterogeneity of Bulk Tumor.
J Thorac Oncol. 2021;16:e67-e68.
PubMed

LEE HY
A Wake-Up Call for Immune Checkpoint Inhibitor-Related Pneumonitis.
J Thorac Oncol. 2021;16:1440-1442.
PubMed

BIRONZO P, Passiglia F, Novello S
Winds From the ORIENT: New Data to Inform RATIONAL Choice?
J Thorac Oncol. 2021;16:1434-1436.
PubMed

UPRETY D, Remon J, Adjei AA
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC.
J Thorac Oncol. 2021;16:1429-1433.
PubMed

LIAO BC, Chih-Hsin Yang J
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:1426-1428.
PubMed

NAKASHIMA K, Tsubata Y, Niihara H, Araki A, et al
Palm Pustules Induced by Pemetrexed.
J Thorac Oncol. 2021;16:1589-1591.
PubMed

POZZESSERE C, Lazor R, Jumeau R, Peters S, et al
Imaging Features of Pulmonary Immune-related Adverse Events.
J Thorac Oncol. 2021;16:1449-1460.
PubMed Abstract available

VANDENHOECK J, van Meerbeeck JP, Fransen E, Raskin J, et al
DNA Methylation as a Diagnostic Biomarker for Malignant Mesothelioma: A Systematic Review and Meta-Analysis.
J Thorac Oncol. 2021;16:1461-1478.
PubMed Abstract available

August 2021

CAMIDGE DR, Kim HR, Ahn MJ, Yang JC, et al
Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.
J Thorac Oncol. 2021 Aug 30. pii: S1556-0864(21)02398.
PubMed Abstract available

DOROSHOW DB, Wei W, Gupta S, Zugazagoitia J, et al
PD-L1 tumor proportion score and overall survival from first-line pembrolizumab in patients with nonsquamous versus squamous non-small cell lung cancer.
J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02392.
PubMed Abstract available

PLANCHARD D, Besse B, Groen HJM, Hashemi SMS, et al
Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer: Updated 5-year survival rates and genomic analysis.
J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02403.
PubMed Abstract available

THOMAS NJ, Myall NJ, Sun F, Patil T, et al
Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.
J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02401.
PubMed Abstract available

KERPEL-FRONIUS A, Tammemagi M, Cavic M, Henschke C, et al
Screening for lung cancer in individuals who never smoked: An IASLC Early Detection and Screening Committee Report.
J Thorac Oncol. 2021 Aug 26. pii: S1556-0864(21)02391.
PubMed Abstract available

SHIRASAWA M, Yoshida T, Shimoda Y, Takayanagi D, et al
Differential Immune-Related Microenvironment Determines PD-1/PD-L1 Blockade Efficacy in Advanced Non-Small Cell Lung Cancer Patients.
J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02373.
PubMed Abstract available

YAMAGUCHI H, Wakuda K, Fukuda M, Kenmotsu H, et al
A phase II study of osimertinib for radiotherapy-naive CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L).
J Thorac Oncol. 2021 Aug 19. pii: S1556-0864(21)02372.
PubMed Abstract available

WALIANY S, Zhu H, Wakelee H, Padda SK, et al
Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
J Thorac Oncol. 2021 Aug 18. pii: S1556-0864(21)02377.
PubMed Abstract available

QUAIFE SL, Dickson JL, Brain KE, Kurtidu C, et al
Psychological targets for lung cancer screening uptake: a prospective longitudinal cohort study.
J Thorac Oncol. 2021 Aug 14. pii: S1556-0864(21)02369.
PubMed Abstract available

HERZOG BH, Devarakonda S, Govindan R
Overcoming chemotherapy resistance in Small Cell Lung Cancer.
J Thorac Oncol. 2021 Aug 3. pii: S1556-0864(21)02333.
PubMed

AREDO JV, Wakelee HA, Han SS
A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
J Thorac Oncol. 2021;16:e59-e60.
PubMed

PELOSI G, Pasini F
Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit.
J Thorac Oncol. 2021;16:e57-e59.
PubMed

SINGH N, Agrawal S, Jiwnani S, Khosla D, et al
Lung Cancer in India.
J Thorac Oncol. 2021;16:1250-1266.
PubMed

BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
Reaction on the Interpretation of the Hippocampus Avoidance Prophylactic Cranial Irradiation Trial in SCLC (NCT01780675).
J Thorac Oncol. 2021;16:e63-e65.
PubMed

MLADKOVA N, Lo S, Brown PD, Gondi V, et al
Hippocampal Avoidance Prophylactic Cranial Irradiation: Interpreting the Evidence.
J Thorac Oncol. 2021;16:e60-e63.
PubMed

COOPER WA, Lantuejoul S, Mino-Kenudson M
Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC-Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?
J Thorac Oncol. 2021;16:1247-1249.
PubMed

RUIZ J, Chan M, Strowd RE
Treatment of Leptomeningeal Metastases: New Hammer, the Same Nail.
J Thorac Oncol. 2021;16:1244-1246.
PubMed

SMIT EF, Belderbos J
Concurrent Chemoradiation, Adjuvant Durvalumab, and KEAP-1/NRF-2 Mutations: A Happy Marriage?
J Thorac Oncol. 2021;16:1242-1243.
PubMed

COLOMBO M, Ndembe G, Broggini M
KRAS Targeting and Resistance: Anticipating the Expectable.
J Thorac Oncol. 2021;16:1239-1241.
PubMed

HUDDAR P, Califano R
Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue.
J Thorac Oncol. 2021;16:1236-1238.
PubMed

SHAVERDIAN N, Offin M, Shepherd AF, Simone CB 2nd, et al
The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
J Thorac Oncol. 2021;16:1392-1402.
PubMed Abstract available

FAN C, Zhao Q, Li L, Shen W, et al
Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier:
J Thorac Oncol. 2021;16:1359-1368.
PubMed Abstract available

YEONG J, Suteja L, Simoni Y, Lau KW, et al
Intratumoral CD39(+)CD8(+) T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC.
J Thorac Oncol. 2021;16:1349-1358.
PubMed Abstract available

KOGA T, Suda K, Fujino T, Ohara S, et al
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
J Thorac Oncol. 2021;16:1321-1332.
PubMed Abstract available

YOTSUKURA M, Asamura H, Motoi N, Kashima J, et al
Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung.
J Thorac Oncol. 2021;16:1312-1320.
PubMed Abstract available

BORZI C, Ganzinelli M, Caiola E, Colombo M, et al
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
J Thorac Oncol. 2021;16:1298-1311.
PubMed Abstract available

July 2021

DZIADZIUSZKO R, Mok T, Peters S, Han JY, et al
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02321.
PubMed Abstract available

PATEL SA, Herynk MH, Cascone T, Saigal B, et al
Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02320.
PubMed Abstract available

SOCINSKI MA, Nishio M, Jotte RM, Cappuzzo F, et al
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02322.
PubMed Abstract available

SMELTZER MP, Lee YS, Faris NR, Fehnel C, et al
Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.
J Thorac Oncol. 2021 Jul 16. pii: S1556-0864(21)02299.
PubMed Abstract available

STEWART CA, Gay CM, Ramkumar K, Cargill KR, et al
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
J Thorac Oncol. 2021 Jul 15. pii: S1556-0864(21)02294.
PubMed Abstract available

JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
PubMed Abstract available

AI X, Wang Q, Cheng Y, Liu X, et al
Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
PubMed Abstract available

POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
PubMed Abstract available

MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
PubMed Abstract available

WANG Y, Li J, Chang S, Dong Y, et al
Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
PubMed Abstract available

ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
PubMed

HANN CL, Burns TF, Dowlati A, Morgensztern D, et al
Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02289.
PubMed Abstract available

PARK HR, Kim TM, Lee Y, Kim S, et al
Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR(T790M)-mutant non-small cell lung cancer.
J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254.
PubMed Abstract available

KUMAR A, Kumar S, Gilja S, Potter A, et al
Reconsidering the American Joint Committee on Cancer 8(th) Edition TNM Staging Manual Classifications for T2b/T3 Non-small-cell Lung Cancer.
J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02283.
PubMed Abstract available

MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
Lung Cancer in Greece.
J Thorac Oncol. 2021;16:1058-1066.
PubMed

UGUEN A
Each RET Break-Apart Fluorescence In Situ Hybridization Probe Requires Proper Interpretation Criteria.
J Thorac Oncol. 2021;16:e55.
PubMed

ZHU VW, Zhang SS, Zhang J, Swensen J, et al
Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.
J Thorac Oncol. 2021;16:e51-e54.
PubMed

DOWLATI A, Chan T
Pursuing Immunotherapeutic Targets in SCLC.
J Thorac Oncol. 2021;16:1056-1057.
PubMed

GRANNIS FW JR
Do Cancer Screening Researchers Have a Continuing Ethical Obligation to Their Study Subjects?
J Thorac Oncol. 2021;16:1053-1055.
PubMed

Dr. Gouri Shankar Bhattacharyya, MD, PhD, FRCP: In Memoriam (October 31, 1958-May 1, 2021).
J Thorac Oncol. 2021;16:1043-1044.
PubMed

LE-RADEMACHER J, Wang X
Time-To-Event Data: An Overview and Analysis Considerations.
J Thorac Oncol. 2021;16:1067-1074.
PubMed Abstract available

GOODWIN D, Rathi V, Conron M, Wright GM, et al
Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing.
J Thorac Oncol. 2021;16:1166-1175.
PubMed Abstract available

YANG SR, Chang JC, Leduc C, Tan KS, et al
Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling.
J Thorac Oncol. 2021;16:1188-1199.
PubMed Abstract available

LINDBERG K, Grozman V, Karlsson K, Lindberg S, et al
The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.
J Thorac Oncol. 2021;16:1200-1210.
PubMed Abstract available

HAN DH, Duan F, Wu Y, Goo JM, et al
Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial.
J Thorac Oncol. 2021;16:1118-1126.
PubMed Abstract available

June 2021

WARREN GW, Lim VS, Chowdhary M, Marwaha G, et al
Brief Report: New Pulmonary Infiltrates Observed on Computed Tomography Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for COVID-19.
J Thorac Oncol. 2021 Jun 21. pii: S1556-0864(21)02232.
PubMed Abstract available

AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
PubMed Abstract available

SU CC, Wu JT, Neal JW, Popat RA, et al
Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
PubMed Abstract available

ANG YLE, Chia PL, Chua KLM, Devanand A, et al
Lung Cancer in Singapore.
J Thorac Oncol. 2021;16:906-911.
PubMed

RAMI-PORTA R, Goldstraw P, Asamura H
Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
J Thorac Oncol. 2021;16:902-905.
PubMed

GRASS GD, Scott JG, Sedor G, Kattan MW, et al
Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose.
J Thorac Oncol. 2021;16:e48-e49.
PubMed

DU Y, Hu Z, Liang J, Zhan C, et al
Noncancer Cells in Tumor Samples May Bias the Predictive Genomic-Adjusted Radiation Dose.
J Thorac Oncol. 2021;16:e47.
PubMed

RYAN BM
In Response: Using Propensity Score Matching to Balance the Baseline Characteristics.
J Thorac Oncol. 2021;16:e46.
PubMed

LIANG J, Hu Z, Zhan C, Wang Q, et al
Using Propensity Score Matching to Balance the Baseline Characteristics.
J Thorac Oncol. 2021;16:e45-e46.
PubMed

BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
J Thorac Oncol. 2021;16:e42-e45.
PubMed

BREEN WG, Brown PD, Laack NN
Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC.
J Thorac Oncol. 2021;16:e41-e42.
PubMed

DEUTSCH E, Cengel KA, Galluzzi L, Levy A, et al
Could Protons Promote Tumor Control by Avoiding Lymphopenia?
J Thorac Oncol. 2021;16:e39-e41.
PubMed

BAUMAN J, Borghaei H
To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:894-896.
PubMed

WARREN GW, Evans WK, Dresler C
Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care.
J Thorac Oncol. 2021;16:891-893.
PubMed

CAMIDGE DR, Otterson GA, Clark JW, Ignatius Ou SH, et al
Crizotinib in Patients With MET-Amplified NSCLC.
J Thorac Oncol. 2021;16:1017-1029.
PubMed Abstract available

FINN SP, Addeo A, Dafni U, Thunnissen E, et al
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
J Thorac Oncol. 2021;16:990-1002.
PubMed Abstract available

STEUER CE, Jegede OA, Dahlberg SE, Wakelee HA, et al
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
J Thorac Oncol. 2021;16:960-967.
PubMed Abstract available

May 2021

JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
PubMed Abstract available

ZHOU C, Wu L, Fan Y, Wang Z, et al
Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
PubMed Abstract available

HERBST RS, Garon EB, Kim DW, Cho BC, et al
5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
PubMed Abstract available

JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
PubMed Abstract available

BARBI J, Patnaik SK, Pabla S, Zollo R, et al
Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
PubMed Abstract available

LU S, Wang J, Yu Y, Yu X, et al
Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
PubMed Abstract available

ZHAO H, Yao W, Min X, Gu K, et al
Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
PubMed Abstract available

LOIOLA DE ALENCAR VT, Camandaroba MPG, Pirolli R, Fogassa CAZ, et al
Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis - the META-L-BRAIN study.
J Thorac Oncol. 2021 May 5. pii: S1556-0864(21)02131.
PubMed Abstract available

OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?"
J Thorac Oncol. 2021;16:e36-e37.
PubMed

PIRKER R, Prosch H, Popper H, Klepetko W, et al
Lung Cancer in Austria.
J Thorac Oncol. 2021;16:725-733.
PubMed

KIM CG, Cho BC, Lim SM
Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
J Thorac Oncol. 2021;16:709-711.
PubMed

LI M, Zhan C, Wang Q
Is the Story of M Descriptors Fulfilled or Finished?
J Thorac Oncol. 2021;16:e36-e37.
PubMed

METOVIC J, Bianchi F, Barella M, Papotti M, et al
SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
J Thorac Oncol. 2021;16:e32-e35.
PubMed

DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
J Thorac Oncol. 2021;16:e31-e32.
PubMed

NISHIO M, Mendus D, Wang L, Socinski MA, et al
Response to Letter to the Editor.
J Thorac Oncol. 2021;16:e30-e31.
PubMed

DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
J Thorac Oncol. 2021;16:e29-e30.
PubMed

SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
Letter Response.
J Thorac Oncol. 2021;16:e28-e29.
PubMed

MISTRY HB
Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
J Thorac Oncol. 2021;16:e27.
PubMed

RIMNER A, Wu AJ, Grills IS
What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
J Thorac Oncol. 2021;16:722-724.
PubMed

WESTEEL V
Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
J Thorac Oncol. 2021;16:719-721.
PubMed

JULOORI A, Vokes EE
Beyond PACIFIC: Uncharted Waters.
J Thorac Oncol. 2021;16:715-718.
PubMed

LIU SY, Wu YL
Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
J Thorac Oncol. 2021;16:712-714.
PubMed

ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
J Thorac Oncol. 2021;16:706-708.
PubMed

MATSUI S, Le-Rademacher J, Mandrekar SJ
Statistical Models in Clinical Studies.
J Thorac Oncol. 2021;16:734-739.
PubMed Abstract available

STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
J Thorac Oncol. 2021;16:784-797.
PubMed Abstract available

BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
J Thorac Oncol. 2021;16:840-849.
PubMed Abstract available

HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
J Thorac Oncol. 2021;16:868-872.
PubMed Abstract available

FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
J Thorac Oncol. 2021;16:860-867.
PubMed Abstract available

NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
J Thorac Oncol. 2021;16:740-763.
PubMed Abstract available

PASSARO A, Mok T, Peters S, Popat S, et al
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
J Thorac Oncol. 2021;16:764-773.
PubMed Abstract available

April 2021

AI X, Pan Y, Shi J, Yang N, et al
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02111.
PubMed Abstract available

YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02107.
PubMed Abstract available

HWANG DM, Albaqer T, Santiago RC, Weiss J, et al
Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer.
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02108.
PubMed Abstract available

QIAO M, Jiang T, Liu X, Mao S, et al
Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02113.
PubMed Abstract available

ANDRUSKA N, Stowe HB, Crockett C, Liu W, et al
Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.
J Thorac Oncol. 2021 Apr 23. pii: S1556-0864(21)02112.
PubMed Abstract available

SAFIRI S, Sohrabi MR, Carson-Chahhoud K, Bettampadi D, et al
Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019.
J Thorac Oncol. 2021 Apr 15. pii: S1556-0864(21)02110.
PubMed Abstract available

PATAER A, Weissferdt A, Vaporciyan AA, Correa AM, et al
Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.
J Thorac Oncol. 2021 Apr 12. pii: S1556-0864(21)02109.
PubMed Abstract available

BAUMEISTER SE, Baurecht H, Nolde M, Alayash Z, et al
Cannabis use, pulmonary function, and lung cancer susceptibility: A Mendelian randomization study.
J Thorac Oncol. 2021 Apr 11. pii: S1556-0864(21)02105.
PubMed Abstract available

MEMMOTT RM, Wolfe AR, Carbone DP, Williams TM, et al
Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02072.
PubMed Abstract available

PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.
J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)01832.
PubMed Abstract available

ALESSI JV, Ricciuti B, Spurr LF, Gupta H, et al
SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02104.
PubMed Abstract available

LIU L, Bai H, Wang C, Seery S, et al
Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02071.
PubMed Abstract available

ODINTSOV I, Mattar MS, Lui AJW, Offin M, et al
Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02068.
PubMed Abstract available

THOMAS PL, Groves SM, Zhang YK, Li J, et al
Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.
J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02066.
PubMed Abstract available

JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
PubMed Abstract available

GOTO T
Lymph Node Dissection for NSCLC at Whose Discretion?
J Thorac Oncol. 2021;16:e25.
PubMed

PAZ-ARES L
Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.
J Thorac Oncol. 2021;16:e24.
PubMed

XU J, Nie H, Wan H
Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.
J Thorac Oncol. 2021;16:e23-e24.
PubMed

QIU H, Li Q, Xiao Y, Wu D, et al
A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
J Thorac Oncol. 2021;16:e21-e23.
PubMed

NAGASAKA M, Ou SI
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
J Thorac Oncol. 2021;16:532-536.
PubMed

CAMIDGE DR
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
J Thorac Oncol. 2021;16:528-531.
PubMed

GADGEEL SM
Patient-Reported Outcomes in the Era of Immunotherapy Trials.
J Thorac Oncol. 2021;16:516-518.
PubMed

FALKSON CB
Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?
J Thorac Oncol. 2021;16:515.
PubMed

PATEL SP, Kelly K
IMpower 132: Loses Power at the Finish Line.
J Thorac Oncol. 2021;16:512-514.
PubMed

PACHECO JM, Schenk EL
CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.
J Thorac Oncol. 2021;16:509-511.
PubMed

SEBASTIAN M, Stratmann JA, Eberhardt WEE
Too Good to be True?
J Thorac Oncol. 2021;16:507-508.
PubMed

LE X
Heterogeneity in MET-Aberrant NSCLC.
J Thorac Oncol. 2021;16:504-506.
PubMed

OU FS, Michiels S, Shyr Y, Adjei AA, et al
Biomarker Discovery and Validation: Statistical Considerations.
J Thorac Oncol. 2021;16:537-545.
PubMed Abstract available

TATEISHI Y, Horita N, Namkoong H, Enomoto T, et al
Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.
J Thorac Oncol. 2021;16:677-685.
PubMed Abstract available

LE X, Negrao MV, Reuben A, Federico L, et al
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
J Thorac Oncol. 2021;16:583-600.
PubMed Abstract available

LAM VK, Zhang J, Wu CC, Tran HT, et al
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
J Thorac Oncol. 2021;16:601-609.
PubMed Abstract available

VILLALBA JA, Shih AR, Sayo TMS, Kunitoki K, et al
Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas.
J Thorac Oncol. 2021;16:619-629.
PubMed Abstract available

MOONEN L, Derks JL, Hermans BCM, Bunnik IM, et al
Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark.
J Thorac Oncol. 2021;16:610-618.
PubMed Abstract available

March 2021

SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
PubMed Abstract available

DY GK, Prasad D, Kumar P, Attwood K, et al
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
J Thorac Oncol. 2021;16:e19-e20.
PubMed

YANG X, Li Y, Duan Q, Zhang Q, et al
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
J Thorac Oncol. 2021;16:e17-e19.
PubMed

SHIELDS MD, Hicks JK, Boyle TA, Haura EB, et al
Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
J Thorac Oncol. 2021;16:e15-e17.
PubMed

UPRETY D
Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
J Thorac Oncol. 2021;16:371-374.
PubMed

REMON J, Hendriks LEL
Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:368-370.
PubMed

ADJEI AA
Controversies in Thoracic Oncology.
J Thorac Oncol. 2021;16:366-367.
PubMed

RAJAN A
Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal.
J Thorac Oncol. 2021;16:352-354.
PubMed

SONG L, Xu Q, Lizaso A, Zhang Y, et al
Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
J Thorac Oncol. 2021;16:349-351.
PubMed

SONG Z, Lu C, Xu CW, Zheng Z, et al
Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy.
J Thorac Oncol. 2021;16:344-348.
PubMed

WANG X, Piantadosi S, Le-Rademacher J, Mandrekar SJ, et al
Statistical Considerations for Subgroup Analyses.
J Thorac Oncol. 2021;16:375-380.
PubMed

NILSSON MB, Robichaux J, Herynk MH, Cascone T, et al
Altered Regulation of HIF-1alpha in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
J Thorac Oncol. 2021;16:439-451.
PubMed Abstract available

NG TL, Johnson A, Nemenoff RA, Hsieh E, et al
Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
J Thorac Oncol. 2021;16:486-491.
PubMed Abstract available

LI W, Guo L, Liu Y, Dong L, et al
Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
J Thorac Oncol. 2021;16:404-418.
PubMed Abstract available

GIACCONE G, Kim C
Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
J Thorac Oncol. 2021;16:483-485.
PubMed Abstract available

SECHI E, Zekeridou A
Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
J Thorac Oncol. 2021;16:381-394.
PubMed Abstract available

February 2021

LEE J, Ahn MJ
A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
J Thorac Oncol. 2021;16:e14.
PubMed

ZHENG MM, Li YS, Sun H, Wu YL, et al
Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
J Thorac Oncol. 2021;16:e12-e14.
PubMed

TSUI DCC, Camidge DR
Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
J Thorac Oncol. 2021;16:194-196.
PubMed

SEQUIST LV, Skates SJ, Haas W
A New Era of Protein-Based Assays for Cancer Early Detection.
J Thorac Oncol. 2021;16:191-193.
PubMed

FERRARA R, Campochiaro C, Garassino MC
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
J Thorac Oncol. 2021;16:183-186.
PubMed

PADDA SK, Reckamp KL
Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.
J Thorac Oncol. 2021;16:178-182.
PubMed

MOK T, Peters S, Camidge DR, Noe J, et al
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
J Thorac Oncol. 2021;16:259-268.
PubMed Abstract available

LI B, Zhang Y, Miao L, Ma L, et al
Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
J Thorac Oncol. 2021;16:310-317.
PubMed Abstract available

BANFILL K, Giuliani M, Aznar M, Franks K, et al
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
J Thorac Oncol. 2021;16:216-227.
PubMed Abstract available

GJYSHI O, Xu T, Elhammali A, Boyce-Fappiano D, et al
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
J Thorac Oncol. 2021;16:269-277.
PubMed Abstract available

PETERS S, Felip E, Dafni U, Tufman A, et al
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology P
J Thorac Oncol. 2021;16:278-288.
PubMed Abstract available

JIANG T, Fang Z, Tang S, Cheng R, et al
Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma.
J Thorac Oncol. 2021;16:237-249.
PubMed Abstract available

OSTRIN EJ, Bantis LE, Wilson DO, Patel N, et al
Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
J Thorac Oncol. 2021;16:228-236.
PubMed Abstract available

LE X, Nilsson M, Goldman J, Reck M, et al
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
J Thorac Oncol. 2021;16:205-215.
PubMed Abstract available

MOI L, Bouchaab H, Mederos N, Nguyen-Ngoc T, et al
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
J Thorac Oncol. 2021;16:318-326.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.